Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 59
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Gait differences between COPD and healthy controls: systematic review and meta-analysis

  • Buekers, Joren
  • Delgado-Ortiz, Laura
  • Megaritis, Dimitrios
  • Polhemus, Ashley Marie
  • Breuls, Sofie
  • Buttery, Sara C.
  • Chynkiamis, Nikolaos
  • Demeyer, Heleen
  • Gimeno Santos, Elena, 1980-
  • Hume, Emily
  • Koch, Sarah
  • Williams, Parris
  • Wuyts, Marieke
  • Hopkinson, Nicholas S.
  • Vogiatzis, Ioannis
  • Troosters, Thierry
  • Frei, Anja
  • García Aymerich, Judith
Background: Despite the importance of gait as a determinant of falls, disability and mortality in older people, understanding of gait impairment in COPD is limited. This study aimed to identify differences in gait characteristics during supervised walking tests between people with COPD and healthy controls. Methods: We searched 11 electronic databases, supplemented by Google Scholar searches and manual collation of references, in November 2019 and updated the search in July 2021. Record screening and information extraction were performed independently by one reviewer and checked for accuracy by a second. Meta-analyses were performed in studies not considered at a high risk of bias. Results: Searches yielded 21 085 unique records, of which 25 were included in the systematic review (including 1015 people with COPD and 2229 healthy controls). Gait speed was assessed in 17 studies (usual speed: 12; fast speed: three; both speeds: two), step length in nine, step duration in seven, cadence in six, and step width in five. Five studies were considered at a high risk of bias. Low-quality evidence indicated that people with COPD walk more slowly than healthy controls at their usual speed (mean difference (MD) -19 cm·s-1, 95% CI -28 to -11 cm·s-1) and at a fast speed (MD -30 cm·s-1, 95% CI -47 to -13 cm·s-1). Alterations in other gait characteristics were not statistically significant. Conclusion: Low-quality evidence shows that people with COPD walk more slowly than healthy controls, which could contribute to an increased falls risk. The evidence for alterations in spatial and temporal components of gait was inconclusive. Gait impairment appears to be an important but understudied area in COPD., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement number 820820. This JU receives support from the European Union's Horizon 2020 research and innovation programme, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The Barcelona Institute for Global Health (ISGlobal) receives support from the Spanish Ministry of Science, Innovation and Universities through the “Centro de Excelencia Severo Ochoa 2019–2023” programme (CEX 2018-000806-S), and support from the Generalitat de Catalunya through the CERCA programme. The views expressed are those of the authors and not necessarily those of the IMI, the European Union, the EFPIA or any associated partners. L. Delgado-Ortiz receives funding from the grant “Contratos Predoctorales de Formación en Investigación en Salud (PFIS) 2021 of the AES with Exp. FI21/00113” from ISCIII, and the European Social Fund Plus (ESF+). Funding information for this article has been deposited with the Crossref Funder Registry.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Connecting real-world digital mobility assessment to clinical outcomes for regulatory and clinical endorsement-the Mobilise-D study protocol

  • Mikolaizak, A. Stefanie
  • García Aymerich, Judith
  • Bosch de Basea i Gómez, Magda, 1982-
  • Gimeno, Elena
  • Mobilise-D consortium
Background: The development of optimal strategies to treat impaired mobility related to ageing and chronic disease requires better ways to detect and measure it. Digital health technology, including body worn sensors, has the potential to directly and accurately capture real-world mobility. Mobilise-D consists of 34 partners from 13 countries who are working together to jointly develop and implement a digital mobility assessment solution to demonstrate that real-world digital mobility outcomes have the potential to provide a better, safer, and quicker way to assess, monitor, and predict the efficacy of new interventions on impaired mobility. The overarching objective of the study is to establish the clinical validity of digital outcomes in patient populations impacted by mobility challenges, and to support engagement with regulatory and health technology agencies towards acceptance of digital mobility assessment in regulatory and health technology assessment decisions. Methods/design: The Mobilise-D clinical validation study is a longitudinal observational cohort study that will recruit 2400 participants from four clinical cohorts. The populations of the Innovative Medicine Initiative-Joint Undertaking represent neurodegenerative conditions (Parkinson's Disease), respiratory disease (Chronic Obstructive Pulmonary Disease), neuro-inflammatory disorder (Multiple Sclerosis), fall-related injuries, osteoporosis, sarcopenia, and frailty (Proximal Femoral Fracture). In total, 17 clinical sites in ten countries will recruit participants who will be evaluated every six months over a period of two years. A wide range of core and cohort specific outcome measures will be collected, spanning patient-reported, observer-reported, and clinician-reported outcomes as well as performance-based outcomes (physical measures and cognitive/mental measures). Daily-living mobility and physical capacity will be assessed directly using a wearable device. These four clinical cohorts were chosen to obtain generalizable clinical findings, including diverse clinical, cultural, geographical, and age representation. The disease cohorts include a broad and heterogeneous range of subject characteristics with varying chronic care needs, and represent different trajectories of mobility disability. Discussion: The results of Mobilise-D will provide longitudinal data on the use of digital mobility outcomes to identify, stratify, and monitor disability. This will support the development of widespread, cost-effective access to optimal clinical mobility management through personalised healthcare. Further, Mobilise-D will provide evidence-based, direct measures which can be endorsed by regulatory agencies and health technology assessment bodies to quantify the impact of disease-modifying interventions on mobility. Trial registration: ISRCTN12051706., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The funding bodies do not have ultimate authority over any activities (study design, collection, management, analysis, interpretation of data, writing of reports and decision to submit for publication. A draft protocol for the clinical validation was provided as part of the grant/funding application. Content in this publication reflects the authors’ view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein. ISGlobal acknowledges support from the Spanish Ministry of Science, Innovation and Universities through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. Heleen Demeyer is a post-doctoral fellow of the FWO Flanders. Heiko Gaßner is supported by the Fraunhofer Internal Programs under Grant No. Attract 044-602140 and 044-602150
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device

  • Kirk, Cameron
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Koch, Sarah
  • Mobilise-D consortium
This study aimed to validate a wearable device's walking speed estimation pipeline, considering complexity, speed, and walking bout duration. The goal was to provide recommendations on the use of wearable devices for real-world mobility analysis. Participants with Parkinson's Disease, Multiple Sclerosis, Proximal Femoral Fracture, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure, and healthy older adults (n = 97) were monitored in the laboratory and the real-world (2.5 h), using a lower back wearable device. Two walking speed estimation pipelines were validated across 4408/1298 (2.5 h/laboratory) detected walking bouts, compared to 4620/1365 bouts detected by a multi-sensor reference system. In the laboratory, the mean absolute error (MAE) and mean relative error (MRE) for walking speed estimation ranged from 0.06 to 0.12 m/s and - 2.1 to 14.4%, with ICCs (Intraclass correlation coefficients) between good (0.79) and excellent (0.91). Real-world MAE ranged from 0.09 to 0.13, MARE from 1.3 to 22.7%, with ICCs indicating moderate (0.57) to good (0.88) agreement. Lower errors were observed for cohorts without major gait impairments, less complex tasks, and longer walking bouts. The analytical pipelines demonstrated moderate to good accuracy in estimating walking speed. Accuracy depended on confounding factors, emphasizing the need for robust technical validation before clinical application.Trial registration: ISRCTN - 12246987., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). SDD, LR, AY were also supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) project IDEA-FAST—Grant Agreement 853981. LA, LR, AY and SDD were also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear (CNTW) NHS Foundation Trust. LA, LR, AY and SDD were also supported by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. This study was also supported by the National Institute for Health Research (NIHR) through the Sheffield Biomedical Research Centre (BRC, Grant Number IS-BRC-1215–20017). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), and from the Generalitat de Catalunya through the CERCA Program. All opinions are those of the authors and not the funders. The content in this publication reflects the authors’ view, and neither IMI nor the European Union, EFPIA, NHS, NIHR, DHSC, or any associated partners are responsible for any use that may be made of the information contained herein.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Construct validity of real-world digital mobility outcomes in patients after proximal femoral fracture: a cross-sectional observational study

  • Eckert, Tobias
  • de las Heras, Martí
  • Alvarez, Paula
  • Buekers, Joren
  • Koch, Sarah
  • García Aymerich, Judith
Digital mobility outcomes (DMOs) offer unique insights into recovery of real-world mobility after proximal femoral fracture (PFF), but their clinical validity remains to be established. This study assessed construct validity (convergent, divergent, and known-groups) of 24 DMOs measuring walking activity (amount, pattern) and gait (pace, rhythm, bout-to-bout variability) in patients within one year after PFF. Patients were recruited from inpatient and outpatient lists at five European sites, resulting in 505 included participants (66% female), with mean age of 77.6 ± 9.4 years and supervised gait speed of 0.7 ± 0.4 m/s. Mobility was monitored over seven days using a single wearable device on the lower back. Convergent and divergent validity analyses were stratified by two groups: acute (≤ 14 days since surgery) and non-acute (≥ 15 days since surgery). Correlations between DMOs and related (clinical- and patient-reported mobility outcomes) and unrelated constructs (hearing impairment and systolic blood pressure) were compared to a priori expected correlations. Known-groups validity was assessed across four recovery phases. The results were evaluated individually by experts and in a subsequent consensus meeting, with 17 of 24 DMOs showing evidence of construct validity in non-acute PFF patients. These findings represent an initial step in a larger process towards regulatory endorsement., This study is part of the Mobilise-D project, which was funded by the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU received support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This work was also supported by the National Institute for Health and Care Research (NIHR) Sheffield Biomedical Research Centre (NIHR203321). ISGlobal acknowledges support from the grant CEX2023-0001290-S funded by MCIN/AEI/ https://doi.org/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. MdlH was funded by European Union-NextGenerationEU, under the Program Investigo (INVESTIGO 2022, AGAUR- ref. BDNS 608313, file 2022 INV-1 00046 - Code 100046TC19). LR is supported by the IMI2 JU project IDEA-FAST (grant agreement 853981). LR is supported by the NIHR Newcastle Biomedical Research Centre based at The Newcastle upon Tyne Hospital National Health Service (NHS) Foundation Trust, Newcastle University, and the Cumbria, Northumberland, and Tyne and Wear NHS Foundation Trust and the NIHR/Wellcome Trust Clinical Research Facility infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. LR received funding from the NIHR Senior Investigator Awards (2020-2024 and 2024-2028). Content in this publication reflects the authors¿ views and neither IMI nor the European Union, EFPIA, NHS, NIHR or the Department of Health and Social Care are responsible for any use that may be made of the information contained herein.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Listening to the patients’ voice: a conceptual framework of the walking experience

  • Delgado-Ortiz, Laura
  • Polhemus, Ashley Marie
  • Keogh, Alison
  • Sutton, Norman
  • Remmele, Werner
  • Hansen, Clint
  • Kluge, Felix
  • Sharrack, Basil
  • Becker, Clemens
  • Troosters, Thierry
  • Maetzler, Walter
  • Rochester, Lynn
  • Frei, Anja
  • Puhan, Milo A.
  • García Aymerich, Judith
Includes supplementary materials for the online appendix., Walking is crucial for an active and healthy ageing, but the perspectives of individuals living with walking impairment are still poorly understood. To identify and synthesise evidence describing walking as experienced by adults living with mobility-impairing health conditions and to propose an empirical conceptual framework of walking experience. We performed a systematic review and meta-ethnography of qualitative evidence, searching seven electronic databases for records that explored personal experiences of walking in individuals living with conditions of diverse aetiology. Conditions included Parkinson’s disease, multiple sclerosis, chronic obstructive pulmonary disease, hip fracture, heart failure, frailty and sarcopenia. Data were extracted, critically appraised using the NICE quality checklist and synthesised using standardised best practices.From 2,552 unique records, 117 were eligible. Walking experience was similar across conditions and described by seven themes: (i) becoming aware of the personal walking experience, (ii) the walking experience as a link between individuals’ activities and sense of self, (iii) the physical walking experience, (iv) the mental and emotional walking experience, (v) the social walking experience, (vi) the context of the walking experience and (vii) behavioural and attitudinal adaptations resulting from the walking experience. We propose a novel conceptual framework that visually represents the walking experience, informed by the interplay between these themes. A multi-faceted and dynamic experience of walking was common across health conditions. Our conceptual framework of the walking experience provides a novel theoretical structure for patient-centred clinical practice, research and public health., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Content in this publication reflects the authors’ view and neither IMI nor the European Union, EFPIA or any associated partners are responsible for any use that may be made of the information contained herein. ISGlobal acknowledges support from the Spanish Ministry of Science, Innovation, and Universities through the ‘Centro de Excelencia Severo Ochoa 2019–2023’ Programme (CEX2018-000806-S) and support from the Generalitat de Catalunya through the CERCA Programme.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Toward a regulatory qualification of real-world mobility performance biomarkers in parkinson's patients using digital mobility outcomes

  • Viceconti, Marco
  • Hernández Penna, Sabina
  • Dartee, Wilhelmus
  • Mazzà, Claudia
  • Caulfield, Brian
  • Becker, Clemens
  • Maetzler, Walter
  • García Aymerich, Judith
  • Davico, Giorgio
  • Rochester, Lynn
Wearable inertial sensors can be used to monitor mobility in real-world settings over extended periods. Although these technologies are widely used in human movement research, they have not yet been qualified by drug regulatory agencies for their use in regulatory drug trials. This is because the first generation of these sensors was unreliable when used on slow-walking subjects. However, intense research in this area is now offering a new generation of algorithms to quantify Digital Mobility Outcomes so accurate they may be considered as biomarkers in regulatory drug trials. This perspective paper summarises the work in the Mobilise-D consortium around the regulatory qualification of the use of wearable sensors to quantify real-world mobility performance in patients affected by Parkinson's Disease. The paper describes the qualification strategy and both the technical and clinical validation plans, which have recently received highly supportive qualification advice from the European Medicines Agency. The scope is to provide detailed guidance for the preparation of similar qualification submissions to broaden the use of real-world mobility assessment in regulatory drug trials., This study was supported by the project Mobilise-D, “Digital sensors to monitor mobility, disease progression”, Grant agreement ID: 820820, funded by the European Commission through the programme H2020-EU.3.1.7.-Innovative Medicines Initiative 2 (IMI2). Author JGA also acknowledge support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Cocreating the visualization of digital mobility outcomes: Delphi-type process with patients

  • Lumsdon, Jack
  • Delgado-Ortiz, Laura
  • García Aymerich, Judith
  • Cantu, Alma
Background: Recent technological advances in wearable devices offer new potential for measuring mobility in real-world contexts. Mobilise-D has validated digital mobility outcomes to provide novel outcomes and end points in clinical research of 4 different long-term health conditions (Parkinson disease, multiple sclerosis, chronic obstructive pulmonary disease, and proximal femoral fracture). These outcomes also provide unique information that is important to patients; however, there is limited literature that explores the optimal methods to achieve this, such as the best way to visualize patients' data. Objective: This study aimed to identify meaningful outcomes for each condition and how to best visualize them from the perspective of end users. Methods: Using a Delphi-type protocol with patients as subject matter experts, we gathered iterative feedback on the cocreation of visualizations through 3 rounds of questionnaires. An open-ended questionnaire was used in round 1 to understand what aspects of mobility were most influenced by their health condition. These responses were mapped onto relevant digital mobility outcomes and walking experiences and then prioritized for visualization. Using patient responses, we worked alongside researchers, clinicians, and a patient advisory group to develop visualizations that depicted a week of mobility data. During rounds 2 and 3, participants rated usefulness and ease of understanding on a 5-point Likert scale and provided unstructured feedback in comment boxes for each visualization. Visualizations were refined using the feedback from round 2 before receiving further feedback in round 3. Results: Participation varied across rounds 1 to 3 (n=48, n=79, and n=78, respectively). Round 1 identified important outcomes and contexts for each health condition, such as walking speed and stride length for people with Parkinson disease or multiple sclerosis and number of steps for people with chronic obstructive pulmonary disease or proximal femoral fracture. The consensus was not reached for any visualization reviewed in round 2 or 3. Feedback was generally positive, and some participants reported that they were able to understand the visualization and interpret what the visualization represented. Conclusions: Through the feedback provided and existing data visualization principles, we developed recommendations for future visualizations of mobility- and health-related data. Visualizations should be readable by ensuring that large and clear fonts are used and should be friendly for people with vision impairments, such as color blindness. Patients have a strong understanding of their own condition and its variability; hence, adding additional factors into visualizations is recommended to better reflect the nuances of a condition. Ensuring that outcomes and visualizations are meaningful requires close collaboration with patients throughout the development process., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking (JU; grant agreement 820820). This JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The content of the current publication reflects the authors’ view, and neither IMI nor the European Union, EFPIA, nor any associated partners are responsible for any use that may be made of the information contained herein. HG was supported by the Fraunhofer Internal Programs (grants Attract 044–602140 and 044–602150). HG also received institutional funding from the Deutsche Forschungsgemeinschaft (German Research Foundation)—SFB 1483—Project-ID 442419336, EmpkinS. LR, AY, and SDD were also supported by the IMI2 JU project IDEA-FAST (grant agreement 853981). LR, AY, and SDD were supported by the National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre based at The Newcastle upon Tyne Hospital National Health Service (NHS) Foundation Trust, Newcastle University, and the Cumbria, Northumberland, and Tyne and Wear NHS Foundation Trust and the NIHR/Wellcome Trust Clinical Research Facility infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. LR received funding from the NIHR Senior Investigator Awards (2020-2024 and 2024-2028). EB was supported by the NIHR Sheffield Biomedical-Research Centre and Clinical Research Facility. The views expressed are those of the authors and not necessarily those of the NHS, NIHR, or the Department of Health and Social Care.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Association of cut-point free metrics and common clinical tests among older adults after proximal femoral fracture

  • Younesian, Hananeh
  • Singleton, David
  • Vereijken, Beatrix
  • García Aymerich, Judith
  • Rochester, Lynn
  • Aursand Berge, Martin
  • Engdal, Monika
  • Buekers, Joren
  • Koch, Sarah
  • Helbostad, Jorunn L.
  • Alvarez, Paula
  • Jansen, Carl-Philipp
  • Aminian, Kamiar
  • Paraschiv-Ionescu, Anisoara
  • Becker, Clemens
  • Caulfield, Brian
  • Mobilise-D consortium
Wearable and lightweight devices facilitate real-world physical activity (PA) assessments. MX metrics, as a cut-point-free parameter, evaluate acceleration above which the most active X minutes are accumulated. It provides insights into the intensity of PA over specific durations. This study evaluated the association of MX metrics and clinical tests in older adults recovering from proximal femoral fracture (PFF). Analyses were conducted on the PFF cohort from the baseline assessment of the Mobilise-D project using an accelerometer-based device. Participants (N = 396) were categorized into four recovery groups: acute, post-acute, extended recovery, and long-term recovery. Mobility capacity was assessed through the 6 min walking test (6MinWT), Short Physical Performance Battery (SPPB), 4-m walking test (4MWT), and hand grip (HG) strength. Mobility perception was evaluated using the Late-Life Function and Disability Instrument (LLFDI). Eight MX metrics (M1-M90) were calculated using the GGIR package in R. Results showed a moderate to strong positive correlation between M1 and M30 and lower limb mobility capacity tests and mobility perception (Lower Extremity domains) particularly in the extended and long-term recovery groups. MX metrics can be used for measuring PA intensity among older adults recovering from PFF. Hence, MX metrics have a high potential for clinical use as personalized PA targets in PFF rehabilitation., H.Y. has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 101034252. This research is supported by Taighde Éireann—Research Ireland. The Mobilise-D consortium received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820820. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Technical validation of real-world monitoring of gait: a multicentric observational study

  • Mazzà, Claudia
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Koch, Sarah
  • Rochester, Lynn
Introduction: Existing mobility endpoints based on functional performance, physical assessments and patient self-reporting are often affected by lack of sensitivity, limiting their utility in clinical practice. Wearable devices including inertial measurement units (IMUs) can overcome these limitations by quantifying digital mobility outcomes (DMOs) both during supervised structured assessments and in real-world conditions. The validity of IMU-based methods in the real-world, however, is still limited in patient populations. Rigorous validation procedures should cover the device metrological verification, the validation of the algorithms for the DMOs computation specifically for the population of interest and in daily life situations, and the users' perspective on the device. Methods and analysis: This protocol was designed to establish the technical validity and patient acceptability of the approach used to quantify digital mobility in the real world by Mobilise-D, a consortium funded by the European Union (EU) as part of the Innovative Medicine Initiative, aiming at fostering regulatory approval and clinical adoption of DMOs.After defining the procedures for the metrological verification of an IMU-based device, the experimental procedures for the validation of algorithms used to calculate the DMOs are presented. These include laboratory and real-world assessment in 120 participants from five groups: healthy older adults; chronic obstructive pulmonary disease, Parkinson's disease, multiple sclerosis, proximal femoral fracture and congestive heart failure. DMOs extracted from the monitoring device will be compared with those from different reference systems, chosen according to the contexts of observation. Questionnaires and interviews will evaluate the users' perspective on the deployed technology and relevance of the mobility assessment. Ethics and dissemination: The study has been granted ethics approval by the centre's committees (London-Bloomsbury Research Ethics committee; Helsinki Committee, Tel Aviv Sourasky Medical Centre; Medical Faculties of The University of Tübingen and of the University of Kiel). Data and algorithms will be made publicly available. Trial registration number: ISRCTN (12246987)., We acknowledge support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. SDD, AY and LRo are also supported by the Newcastle Biomedical Research Centre (BRC) based at Newcastle upon Tyne and Newcastle University. CM, BS, LVG and EB are also supported by the Sheffield Biomedical Research Centre (BRC) based at the Sheffield Teaching Hospital and the University of Sheffield. The work was also supported by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust and the CRF at the Sheffield Teaching Hospital. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care or the funders.This study was co-funded by the European Union’s Horizon 2020 research and innovation programme and EFPIA via the Innovative Medicine Initiative 2 (Mobilise-D project, grant number IMI22017-13-7-820820). The views expressed are those of the authors and not necessarily those of the IMI, the European Union, the EFPIA, or any Associated Partners. We acknowledge the support of Grünenthal GmbH via the funding of a PhD scholarship directly dedicated to the technical validation protocol.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Walking-related digital mobility outcomes as clinical trial endpoint measures: protocol for a scoping review

  • Polhemus, Ashley Marie
  • Bosch de Basea i Gómez, Magda, 1982-
  • Delgado-Ortiz, Laura
  • García Aymerich, Judith
  • Koch, Sarah
  • Frei, Anja
Introduction: Advances in wearable sensor technology now enable frequent, objective monitoring of real-world walking. Walking-related digital mobility outcomes (DMOs), such as real-world walking speed, have the potential to be more sensitive to mobility changes than traditional clinical assessments. However, it is not yet clear which DMOs are most suitable for formal validation. In this review, we will explore the evidence on discriminant ability, construct validity, prognostic value and responsiveness of walking-related DMOs in four disease areas: Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary disease and proximal femoral fracture. Methods and analysis: Arksey and O'Malley's methodological framework for scoping reviews will guide study conduct. We will search seven databases (Medline, CINAHL, Scopus, Web of Science, EMBASE, IEEE Digital Library and Cochrane Library) and grey literature for studies which (1) measure differences in DMOs between healthy and pathological walking, (2) assess relationships between DMOs and traditional clinical measures, (3) assess the prognostic value of DMOs and (4) use DMOs as endpoints in interventional clinical trials. Two reviewers will screen each abstract and full-text manuscript according to predefined eligibility criteria. We will then chart extracted data, map the literature, perform a narrative synthesis and identify gaps. Ethics and dissemination: As this review is limited to publicly available materials, it does not require ethical approval. This work is part of Mobilise-D, an Innovative Medicines Initiative Joint Undertaking which aims to deliver, validate and obtain regulatory approval for DMOs. Results will be shared with the scientific community and general public in cooperation with the Mobilise-D communication team. Registration: Study materials and updates will be made available through the Center for Open Science's OSFRegistry (https://osf.io/k7395)., The MOBILISE-D project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 820 820. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). HD is a postdoctoral research fellow of the FWO-Flanders. JGA, MBdB, LDO and SK acknowledge support from the Spanish Ministry of Science, Innovation and Universities through the 'Centro de Excelencia Severo Ochoa 2019–2023' Programme (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Programme.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Laboratory and free-living gait performance in adults with COPD and healthy controls

  • Buekers, Joren
  • Koch, Sarah
  • García Aymerich, Judith
Background: Gait characteristics are important risk factors for falls, hospitalisations and mortality in older adults, but the impact of COPD on gait performance remains unclear. We aimed to identify differences in gait characteristics between adults with COPD and healthy age-matched controls during 1) laboratory tests that included complex movements and obstacles, 2) simulated daily-life activities (supervised) and 3) free-living daily-life activities (unsupervised). Methods: This case-control study used a multi-sensor wearable system (INDIP) to obtain seven gait characteristics for each walking bout performed by adults with mild-to-severe COPD (n=17; forced expiratory volume in 1 s 57±19% predicted) and controls (n=20) during laboratory tests, and during simulated and free-living daily-life activities. Gait characteristics were compared between adults with COPD and healthy controls for all walking bouts combined, and for shorter (≤30 s) and longer (>30 s) walking bouts separately. Results: Slower walking speed (-11 cm·s-1, 95% CI: -20 to -3) and lower cadence (-6.6 steps·min-1, 95% CI: -12.3 to -0.9) were recorded in adults with COPD compared to healthy controls during longer (>30 s) free-living walking bouts, but not during shorter (≤30 s) walking bouts in either laboratory or free-living settings. Double support duration and gait variability measures were generally comparable between the two groups. Conclusion: Gait impairment of adults with mild-to-severe COPD mainly manifests during relatively long walking bouts (>30 s) in free-living conditions. Future research should determine the underlying mechanism(s) of this impairment to facilitate the development of interventions that can improve free-living gait performance in adults with COPD., Support statement: This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement number 820820. This JU receives support from the European Union's Horizon 2020 research and innovation programme, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). S. Del Din and L. Rochester were also supported by the Innovative Medicines Initiative 2 (IMI2) JU project IDEA-FAST – grant agreement 853981. S. Del Din, L. Alcock and L. Rochester were also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear NHS Foundation Trust, and by the NIHR/Welcome Trust Clinical Research Facility infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. C. Mazzà and E. Buckley were also supported by the Sheffield BRC based at the Sheffield Teaching Hospital and the University of Sheffield. H. Demeyer is a post-doctoral research fellow of the Flemish Research Foundation (FWO Flanders). The Barcelona Institute for Global Health (ISGlobal) receives support from the Spanish Ministry of Science, Innovation and Universities through the “Centro de Excelencia Severo Ochoa 2019–2023” Programme (CEX 2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Programme. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health, the IMI, the European Union, the EFPIA or any Associated Partners. Funding information for this article has been deposited with the Crossref Funder Registry.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Digital assessment of real-world walking in people with impaired mobility: How many hours and days are needed?

  • Buekers, Joren
  • Koch, Sarah
  • Marchena, José
  • Lemos, Jorge
  • García Aymerich, Judith
Background: Impaired mobility increases falls and mortality risk. However, guidelines to reliably assess real-world walking activity and gait remain undefined. We aimed to (i) determine the minimum daily wear time during waking hours (7:00–22:00) for a valid measurement day, (ii) identify the minimum number of valid days, and (iii) weekend days, to reliably assess weekly walking activity and gait parameters, and (iv) provide recommendations for reliable real-world walking assessments. Methods: Participants with chronic obstructive pulmonary disease (n = 565), multiple sclerosis (n = 558), Parkinson’s disease (n = 543) or proximal femoral fracture (n = 487) from 10 countries were asked to wear a single wearable device on the lower back, 24 h/day for seven days, resulting in 13,191 measurement days. The Mobilise-D processing pipeline was used to obtain 24 daily walking activity and gait parameters. Minimum daily wear time was determined as the highest wear time category that did not statistically change parameter values. Intraclass correlation coefficients ≥ 0.80 determined the minimum number of valid measurement and weekend days. Results: The minimum daily wear time varied between “no requirement” (13% of parameter-condition combinations) and > 14 h (19%), with higher requirements for walking activity than gait parameters. The minimum number of days ranged from 1 (17%) to > 7 days (6%), and was higher for parameters that are yet to be clinically validated. There was no evidence of a weekend nor health condition effect on parameter reliability. Conclusions: For studies involving multiple walking activity and gait parameters or health conditions, expert consensus recommends a minimum of > 12 h of daily wear time across ≥ 3 days. For studies that involve specific parameters or health conditions, individual recommendations are provided within the manuscript. Supplementary Information: The online version contains supplementary material available at 10.1186/s12966-025-01851-3., This work was supported by the Mobilise-D project that received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The Barcelona Institute for Global Health (ISGlobal) receives support from the grant CEX2023-0001290-S funded by MCIN/AEI/https://doi.org/10.13039/5011 00011033, and support from the Generalitat de Catalunya through the CERCA rogram. Joren Buekers (FJC2021-046458-I) and Sarah Koch (IJC2020-044363-I) received funding from the Juan de la Cierva Formación and Incorporación, respectively, financed by MICIU/AEI/https://doi.org/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR. This paper presents independent research supported by the National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre (BRC), and the NIHR Sheffield BRC. The NIHR Newcastle BRC is a partnership between Newcastle Hospitals NHS Foundation Trust, Newcastle University, and Cumbria, Northumberland and Tyne and Wear NHS Foundation Trust and is funded by the NIHR. The research was also supported by the NIHR Sheffield Biomedical Research Centre based at the Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield and carried out at the NIHR Sheffield Clinical Research Facility at the Sheffield Teaching Hospitals NHS Foundation Trust. LR, AY and SDD were also supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) project IDEA-FAST - Grant Agreement 853981. LR, AY and SDD were supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear (CNTW) NHS Foundation Trust and, the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. SDD was supported by the UK Research and Innovation (UKRI) Engineering and Physical Sciences Research Council (EPSRC) (Grant Ref: EP/W031590/1, Grant Ref: EP/X031012/1 and Grant Ref: EP/X036146/1). AY is also supported by the Michael J Fox Foundation (grant references MJFF-022735 & MJFF-022737), UK Engineering and Physical Sciences Research Council (EPSRC), grant number EP/X036146/1, Intercept Pharmaceuticals, NIHR HTA (grant reference NIHR129175). She is in receipt of grants from Parkinson's UK, Weston Brain Institute, Dunhill Medical Trust and Cure Parkinson's Trust. HD is a post-doctoral researcher of FWO Flanders (12ZW822N). The views expressed are those of the authors and not necessarily those of the IMI, the European Union, the EFPIA, NHS, NIHR, the Department of Health and Social Care or any Associated Partners
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Can digital mobility assessment enhance the clinical assessment of disease severity in Parkinson's disease?

  • Kirk, Cameron
  • Rehman, Rana Zia Ur
  • Galna, Brook
  • Alcock, Lisa
  • Ranciati, Saverio
  • Palmerini, Luca
  • García Aymerich, Judith
  • Hansen, Clint
  • Schaeffer, Eva
  • Berg, Daniela
  • Maetzler, Walter
  • Rochester, Lynn
  • Del Din, Silvia
  • Yarnall, Alison J.
Background: Real-world walking speed (RWS) measured using wearable devices has the potential to complement the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS III) for motor assessment in Parkinson's disease (PD). Objective: Explore cross-sectional and longitudinal differences in RWS between PD and older adults (OAs), and whether RWS was related to motor disease severity cross-sectionally, and if MDS-UPDRS III was related to RWS, longitudinally. Methods: 88 PD and 111 OA participants from ICICLE-GAIT (UK) were included. RWS was evaluated using an accelerometer at four time points. RWS was aggregated within walking bout (WB) duration thresholds. Between-group-comparisons in RWS between PD and OAs were conducted cross-sectionally, and longitudinally with mixed effects models (MEMs). Cross-sectional association between RWS and MDS-UPDRS III was explored using linear regression, and longitudinal association explored with MEMs. Results: RWS was significantly lower in PD (1.04 m/s) in comparison to OAs (1.10 m/s) cross-sectionally. RWS significantly decreased over time for both cohorts and decline was more rapid in PD by 0.02 m/s per year. Significant negative relationship between RWS and the MDS-UPDRS III only existed at a specific WB threshold (30 to 60 s, β= - 3.94 points, p = 0.047). MDS-UPDRS III increased significantly by 1.84 points per year, which was not related to change in RWS. Conclusion: Digital mobility assessment of gait may add unique information to quantify disease progression remotely, but further validation in research and clinical settings is needed., This work is also supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) project Mobilise-D that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Content in this publication reflects the authors’ view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Digital mobility outcomes to describe real-world walking during recovery from a hip fracture: the Mobilise-D perspective

  • Becker, Clemens
  • García Aymerich, Judith
  • Delgado-Ortiz, Laura
  • Koch, Sarah
  • Buekers, Joren
  • Alvarez, Paula
  • Marcuzzi, Anna
Purpose: The burden of disease caused by fragility fractures, and hip fractures in particular, is significant both from a personal and a societal perspective. Digital technologies such as wearable devices now allow a real-world assessment of walking and physical mobility, describing temporal and spatial measures. Built on a transparent technical validation, the Mobilise-D consortium validated a set of digital mobility outcomes (DMOs) alongside a longitudinal clinical validation study (CVS). This article provides a description of DMOs along with supervised mobility assessment and patient-reported outcomes collected at entry of the CVS study in a sample of home-dwelling participants with a proximal femoral fracture (PFF) recruited within 1 year after surgery. Methods: Participants who underwent surgical treatment for a low-energy PFF were recruited from five sites in three high-income European countries. The first visit encompassed a clinical assessment (~ 3 h) and subsequent 7-day measurement of real-world mobility with a single wearable device. We categorized participants into four recovery phases according to the assessment time after surgery: acute phase (≤ 14 days after surgery, hospital stay), post-acute phase (15-42 days after surgery, mostly rehabilitation), extended recovery phase (43-182 days post-surgery, typically post-discharge at home), and long-term recovery phase (183-365 days post-surgery). All variables were reported descriptively for each phase using mean and standard deviation or median and 25th-75th percentile depending on their distribution. Results: We enrolled 564 PFF participants (66% women). The mean age was 77.5 (SD 9.6) years. Almost 90% of all participants (n = 505) had a valid digital mobility assessment (wear time of > 12 h per day and at least 3 valid days). DMO domains such as amount (e.g., number of steps), pace (e.g., walking speed), and pattern (bout distribution) demonstrated large differences across phases. Conclusions: The observed variation in walking amount and pace and pattern across recovery phases indicate that DMOs provide a granular analysis of real-world mobility of hip fracture survivors. When confirmed by longitudinal analyses, including results on minimal important differences, the use of selected DMOs will provide a novel approach for monitoring, predictive modelling, prognosis, stratification, and evaluation of clinical trials and hip fracture services., Open Access funding enabled and organized by Projekt DEAL. This study was part of the Mobilise-D project, which was funded by the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). SDD and LR were also supported by the IDEA-FAST project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 853981.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A Roadmap to inform development, validation and approval of digital mobility outcomes: The Mobilise-D approach

  • Rochester, Lynn
  • Mazzà, Claudia
  • Mueller, Arne
  • Caulfield, Brian
  • McCarthy, Marie
  • Becker, Clemens
  • Miller, Ram
  • Piraino, Paolo
  • Viceconti, Marco
  • Dartee, Wilhelmus
  • García Aymerich, Judith
  • Aydemir, Aida A.
  • Vereijken, Beatrix
  • Arnera, Valdo
  • Ammour, Nadir
  • Jackson, Michael
  • Hache, Tilo
  • Roubenoff, Ronenn
Health care has had to adapt rapidly to COVID-19, and this in turn has highlighted a pressing need for tools to facilitate remote visits and monitoring. Digital health technology, including body-worn devices, offers a solution using digital outcomes to measure and monitor disease status and provide outcomes meaningful to both patients and health care professionals. Remote monitoring of physical mobility is a prime example, because mobility is among the most advanced modalities that can be assessed digitally and remotely. Loss of mobility is also an important feature of many health conditions, providing a read-out of health as well as a target for intervention. Real-world, continuous digital measures of mobility (digital mobility outcomes or DMOs) provide an opportunity for novel insights into health care conditions complementing existing mobility measures. Accepted and approved DMOs are not yet widely available. The need for large collaborative efforts to tackle the critical steps to adoption is widely recognised. Mobilise-D is an example. It is a multidisciplinary consortium of 34 institutions from academia and industry funded through the European Innovative Medicines Initiative 2 Joint Undertaking. Members of Mobilise-D are collaborating to address the critical steps for DMOs to be adopted in clinical trials and ultimately health care. To achieve this, the consortium has developed a roadmap to inform the development, validation and approval of DMOs in Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary disease and recovery from proximal femoral fracture. Here we aim to describe the proposed approach and provide a high-level view of the ongoing and planned work of the Mobilise-D consortium. Ultimately, Mobilise-D aims to stimulate widespread adoption of DMOs through the provision of device agnostic software, standards and robust validation in order to bring digital outcomes from concept to use in clinical trials and health care., The MOBILISE-D project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 820820. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Walking into aging: real-world mobility patterns and digital benchmarks from the InCHIANTI Study

  • Albites-Sanabria, Jose
  • Palumbo, Pierpaolo
  • Bandinelli, Stefania
  • D'Ascanio, Ilaria
  • Mellone, Sabato
  • Paraschiv-Ionescu, Anisoara
  • Küderle, Arne
  • Cereatti, Andrea
  • Del Din, Silvia
  • Kluge, Felix
  • Gazit, Eran
  • Jansen, Carl-Philipp
  • Delgado-Ortiz, Laura
  • García Aymerich, Judith
  • Rochester, Lynn
  • Klenk, Jochen
  • Ferrucci, Luigi
  • Becker, Clemens
  • Chiari, Lorenzo
  • Palmerini, Luca
Mobility is a cornerstone of health and quality of life, particularly in older adults. Digital mobility outcomes (DMOs) from real-world walking data offer crucial insights into the functional status and early markers of mobility decline. This study provides reference values for walking activity, pace, rhythm, and gait bout-to-bout variability in community-dwelling older adults and evaluates the effects of age, sex, height, and weight on these parameters. Using data from 200 older adults (aged 65-94 years) from the InCHIANTI Study and applying the Mobilise-D computational pipeline, we analyzed real-world walking over a week. Significant differences by sex and age were found, with males showing higher walking activity in younger age groups (65-74 and 75-84 years) but not in the oldest group (85-94 years). Additionally, we observed non-linear trends in mobility metrics with age, indicating an accelerated reduction in mobility at certain age ranges. These findings underscore the importance of monitoring real-world walking data to pinpoint critical periods of mobility decline and guide targeted interventions. This work offers valuable benchmarks for clinical assessments and future research., We want to acknowledge the participants who volunteered to take part in the clinical studies. Their contribution has been vital to the successful completion of the present study. The InCHIANTI baseline study (1998–2000) was supported as a “targeted project” (ICS110.1/RF97.71) by the Italian Ministry of Health and in part by the U.S. National Institute on Aging (Contracts: 263 MD 9164 and 263 MD 821336); the InCHIANTI follow-up study 1 (2001–2003) was funded by the U.S. National Institute on Aging (Contracts: N.1-AG[1]1-1 and N.1-AG-1-2111); the InCHIANTI follow-up study 4 and 5 were supported by the Agency for Regional Health Care of Tuscany (Reg. n° 586/R, 26/10/2012). This research was co-funded by the Italian Complementary National Plan PNC-I.1 Research initiatives for innovative technologies and pathways in the health and welfare sector” D.D. 931 of 06/06/2022, DARE - DigitAl lifelong pRevEntion initiative, code PNC0000002, CUP: B53C22006450001. The study has been funded in part by the European Union (Seventh Framework Program (FP7/2007-2013) under grant agreement No.: 288940 (FARSEEING project)), and by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820820 (Mobilise[1]D). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. S.D.D. was also supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) project IDEA-FAST - Grant Agreement 853981 and by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear (CNTW) NHS Foundation Trust. S.D.D. was supported by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. S.D.D. was also supported by the UK Research and Innovation (UKRI) Engineering and Physical Sciences Research Council (EPSRC) (Grant Ref: EP/W031590/1, Grant Ref: EP/X031012/1 and Grant Ref: EP/X036146/1).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving?

  • Jaeger, Simon U.
  • Wohlrab, Martin
  • Schoene, Daniel
  • Tremmel, Roman
  • Chambers, Michael
  • Leocani, Letizia
  • Corriol-Rohou, Solange
  • Klenk, Jochen
  • Sharrack, Basil
  • García Aymerich, Judith
  • Rochester, Lynn
  • Maetzler, Walter
  • Puhan, Milo A.
  • Schwab, Matthias
  • Becker, Clemens
Background: Mobility is defined as the ability to independently move around the environment and is a key contributor to quality of life, especially in older age. The aim of this study was to evaluate the use of mobility as a decisive outcome for the marketing authorisation of drugs by the European Medicines Agency (EMA). Methods: Fifteen therapeutic areas which commonly lead to relevant mobility impairments and alter the quantity and/or the quality of walking were selected: two systemic neurological diseases, four conditions primarily affecting exercise capacity, seven musculoskeletal diseases and two conditions representing sensory impairments. European Public Assessment Reports (EPARs) published by the EMA until September 2020 were examined for mobility endpoints included in their 'main studies'. Clinical study registries and primary scientific publications for these studies were also reviewed. Results: Four hundred and eighty-four EPARs yielded 186 relevant documents with 402 'main studies'. The EPARs reported 153 primary and 584 secondary endpoints which considered mobility; 70 different assessment tools (38 patient-reported outcomes, 13 clinician-reported outcomes, 8 performance outcomes and 13 composite endpoints) were used. Only 15.7% of those tools distinctly informed on patients' mobility status. Out of 402, 105 (26.1%) of the 'main studies' did not have any mobility assessment. Furthermore, none of these studies included a digital mobility outcome. Conclusions: For conditions with a high impact on mobility, mobility assessment was given little consideration in the marketing authorisation of drugs by the EMA. Where mobility impairment was considered to be a relevant outcome, questionnaires or composite scores susceptible to reporting biases were predominantly used., S.J., M.W., and R.T. are partly supported by the Robert Bosch Stiftung Stuttgart. M.W. reports grants from HORIZON2020 IMI No. 820820, during the conduct of the study. D.S. reports grants from HORIZON2020 IMI No. 820820, during the conduct of the study. M.C. reports personal fees from Takeda Pharmaceuticals, during the conduct of the study; personal fees from Takeda Pharmaceuticals, outside the submitted work. J.K. reports grants from HORIZON2020 IMI No. 820820, during the conduct of the study. J.G.A. reports grants from HORIZON2020 IMI No. 820820, and from AstraZeneca, Chiesi, Esteve, outside the submitted work. W.M. receives or received funding from the European Union, the German Federal Ministry of Education of Research, Michael J. Fox Foundation, Robert Bosch Foundation, Neuroalliance, Lundbeck and Janssen. He received speaker honoraria from Abbvie, Bayer, GlaxoSmithKline, Licher MT, Rölke Pharma and UCB, was invited to Advisory Boards of Abbvie, Biogen, Lundbeck and Market Access & Pricing Strategy GmbH, and is an advisory board member of the Critical Path for Parkinson’s Consortium. He serves as the co-chair of the MDS Technology Task Force. M.P. reports grants from HORIZON2020 IMI No. 820820, outside the submitted work. M.S. is supported by the Robert Bosch Stiftung Stuttgart and reports grants from HORIZON2020 IMI 2 Mobilise D, during the conduct of the study, and grants and non-financial support from Green Cross WellBeing Co. Ltd., Gilead Sciences Inc., Robert Bosch GmbH, and CORAT Therapeutics GmbH, as well as other from Agena Bioscience GmbH, outside the submitted work. C.B. disclosed consultation from E. Lilly and speaker fees from Amgen, Nutricia and Pfizer reports grants from HORIZON2020 IMI No. 820820, during the conduct of the study.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Evaluating the accuracy and reliability of real-world digital mobility outcomes in older adults after hip fracture: Cross-sectional observational study

  • Berge, Martin A.
  • García Aymerich, Judith
  • Koch, Sarah
  • Vereijken, Beatrix
Background: Algorithms estimating real-world digital mobility outcomes (DMOs) are increasingly validated in healthy adults and various disease cohorts. However, their accuracy and reliability in older adults after hip fracture, who often walk slowly for short durations, is underexplored. Objective: This study examined DMO accuracy and reliability in a hip fracture cohort considering walking bout (WB) duration, physical function, days since surgery, and walking aid use. Methods: In total, 19 community-dwelling participants were real-world monitored for 2.5 hours using a lower back wearable device and a reference system combining inertial modules, distance sensors, and pressure insoles. A total of 6 DMO estimates from 164 WBs from 58% (11/19) of the participants (aged 71-90 years; assessed 32-390 days after surgery; Short Physical Performance Battery [SPPB] scores of 3-12; gait speed range 0.39-1.34 m/s) were assessed against the reference system at the WB and participant level. We stratified by WB duration (all WBs, WBs of >10 seconds, WBs of 10-30 seconds, and WBs of >30 seconds) and lower versus higher SPPB scores and observed whether days since surgery and walking aid use affected DMO accuracy and reliability. Results: Across WBs, walking speed and distance ranged from 0.25 to 1.29 m/s and from 1.7 to 436.5 m, respectively. Estimation of walking speed, cadence, stride duration, number of steps, and distance stratified by WB duration showed intraclass correlation coefficients (ICCs) ranging from 0.50 to 0.99 and mean relative errors (MREs) from -6.9% to 12.8%. Stride length estimation showed poor reliability, with ICCs ranging from 0.30 to 0.49 and MREs from 6.1% to 13.2%. Walking speed and distance ICCs in the higher-SPPB score group ranged from 0.85 to 0.99, and MREs ranged from -10.1% to -1.7%. In the lower-SPPB score group, walking speed and distance ICCs ranged from 0.17 to 0.99, and MREs ranged from 13.5% to 32.6%. There was no discernible effect of time since surgery or walking aid use. Conclusions: In total, 5 accurate and reliable real-world DMOs were identified in older adults after hip fracture: walking speed, cadence, stride duration, number of steps, and distance. Accuracy and reliability of most DMOs improved when excluding WBs of <10 seconds and were higher for WBs of >30 seconds than for WBs of 10 to 30 seconds and for participants with higher physical function. DMOs capture daily gait as early as 1 month after surgery also in people using walking aids. However, as most WBs in this cohort were short, there was a trade-off between improving accuracy and reliability by excluding short WBs and losing a substantial amount of data. These results have important implications for establishing the clinical validity of DMOs and evaluating the effects of interventions on daily-life gait, thereby facilitating the design of optimal care pathways., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking under grant 820820. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations. The authors thank the Mobilise-D technical validation study team of work package 2, all participants who devoted their time and energy to this taxing protocol in times of COVID-19, and Miriam Dinger at the Robert Bosch Foundation for Medical Research and Dr Tim Klüter at University Hospital Schleswig-Holstein for their indispensable help in recruiting patients. MAB acknowledges ChatGPT, an artificial intelligence model by OpenAI, for suggestions that helped improve the clarity of some sentences in this paper. SDD and LR were also supported by the Identifying Digital Endpoints to Assess Fatigue, Sleep, and Activities in Daily Living in Neurodegenerative Disorders and Immune-Mediated Inflammatory Diseases project that has received funding from the IMI 2 Joint Undertaking under grant agreement 853981. LR is a National Institute for Health and Care Research (NIHR) senior investigator. Both SDD and LR were supported by the NIHR Newcastle Biomedical Research Centre based at the Newcastle upon Tyne Hospitals National Health Service (NHS) Foundation Trust; Newcastle University; and the Cumbria, Northumberland, Tyne, and Wear NHS Foundation Trust. SDD and LR were also supported by the NIHR and Wellcome Trust Clinical Research Facility infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. SDD was supported by the UK Research and Innovation Engineering and Physical Sciences Research Council (grant reference EP/X031012/1 and EP/X036146/1). The Barcelona Institute for Global Health acknowledges support from grant CEX2018-000806-S funded by the Ministry of Science, Innovation, and Universities and the State Research Agency (MCIN/AEI/10.13039/501100011033) and support from the Government of Catalonia through the Research Centers of Catalonia program. The views expressed in this publication are those of the authors and do not necessarily reflect those of the IMI, the European Union, the European Federation of Pharmaceutical Industries and Associations, any associated partners, the NIHR, or the Department of Health and Social Care, who are not responsible for any use that may be made of the information contained herein.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

How do people with COPD walk? A European study on digitally measured real-world gait

  • Delgado-Ortiz, Laura
  • Buekers, Joren
  • Gimeno Santos, Elena, 1980-
  • Koch, Sarah
  • García Aymerich, Judith
Background: The amount of walking that people with COPD do is reduced. However, data on their manner of walking (i.e. gait) are still lacking. We characterised real-world gait in COPD by assessing levels and distributions of gait parameters, and comparing them across COPD severity and with healthy peers. Methods: 549 people with COPD from seven European sites and 19 healthy older adults wore single wearable devices (either Axivity AX6 or DynaPort MoveMonitor MM+) continuously for 1 week, from which we identified walking bouts, calculated 15 digital mobility outcomes (DMOs) aggregated at the weekly level, and compared them across COPD severity levels and with healthy peers. Results: Of the participants with COPD, 37% were female with a mean±sd age of 68±8 years and a post-bronchodilator forced expiratory volume in 1 s of 54±20% predicted. All gait DMOs were normally distributed and exhibited variability between participants (e.g. mean±sd walking speed of 0.83±0.12 m·s-1, ranging from 0.48 to 1.20 m·s-1). Walking speed and cadence DMOs were lower with increasing disease severity (e.g. mean±sd walking speed of 0.88±0.11, 0.85±0.12, 0.80±0.12 and 0.78±0.14 m·s-1 across Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades 1 to 4, p<0.001; mean±sd cadence of 93±6, 91±6 and 89±7 steps·min-1 across GOLD A, B and E, p=0.013). Stride length and duration varied across COPD severity levels. Walking speed and cadence bout-to-bout variability only varied across dyspnoea severity levels. In a secondary analysis, we compared DMO data from people with COPD to a convenience sample of 19 healthy older adults (47% women, mean age 71±6 years) and found that walking speed and cadence varied between participants with COPD and healthy adults (e.g. mean±sd walking speed 0.83±0.12 versus 0.90±0.12 m·s-1, p=0.041). Conclusion: In people with COPD, gait DMOs are normally distributed and worsen as disease advances. Moreover, walking speed and cadence DMOs are significantly altered when compared to healthy peers. Further research should elucidate which DMOs can be improved with treatments to enhance mobility and reduce adverse events., This work was supported by the Mobilise-D project that has received funding from the IMI2 JU under grant agreement number 820820. This JU receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The content of the current publication reflects the authors’ view and neither IMI nor the European Union, EFPIA or any associated partners are responsible for any use that may be made of the information contained herein. ISGlobal acknowledges support from the grant CEX2023-0001290-S funded by CIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Programme. L. Delgado-Ortiz received funding from the grant “Contratos Predoctorales de Formación en Investigación en Salud (PFIS) 2021 of the AES with Exp. FI21/00113” from Instituto de Salud Carlos III, and the European Social Fund Plus. L. Rochester and S. Del Din were supported by the NIHR Newcastle BRC based at Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and Cumbria, Northumberland and Tyne and Wear NHS Foundation Trust. H. Demeyer is a post-doctoral fellow of FWO Flanders (12ZW822N). S. Koch received funding from the Juan de la Cierva Incorporación Fellowship of the Spanish Ministry of Research and Innovation (IJC2020-044363-I). J. Buekers received funding from the grant “FJC2021-046458-I” financed by MICIU/AEI/10.13039/501100011033 and by the European Union NextGeneration EU/PRTR. Funding Information for this article has been deposited with the Crossref Funder Registry.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The construct validity of real-world digital mobility outcomes in people with COPD

  • Megaritis, Dimitrios
  • de las Heras, Martí
  • Alcaraz-Serrano, Victoria
  • Alvarez, Paula
  • Buekers, Joren
  • Delgado-Ortiz, Laura
  • Gimeno Santos, Elena, 1980-
  • Josa-Culleré, Alícia
  • Koch, Sarah
  • Lemos, Jorge
  • García Aymerich, Judith
Background: Recent advances in wearable technologies make it possible to accurately quantify real-world mobility performance through technically validated digital mobility outcomes (DMOs). The aim of the present study was to evaluate the construct validity (convergent, divergent, and known-groups validity) of 24 DMOs quantifying walking activity (amount and pattern) and gait (pace, rhythm and bout-to-bout variability) in people with COPD. Methods: Part of the Mobilise-D observational cohort study, people with COPD, recruited from seven European sites, wore an activity monitor for 7 days during daily life. Functional capacity, health status, dyspnoea, lung function, quadriceps torque and experience of difficulty with physical activity were used as constructs for convergent validity testing (Pearson/Spearman correlation coefficients). Diastolic blood pressure was used as an unrelated construct for divergent validity (criterion: |r|<0.2). Known-groups validity was evaluated across Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages (I-IV), GOLD ABE and modified Medical Research Council dyspnoea grades (linear models with p-for-trend). Results: 549 participants (37% females), had mean±sd age of 68±8 years, post-bronchodilator forced expiratory volume in 1 s (FEV1) 54±20% predicted and 6-min walk distance 416±119 m. Convergent validity was supported for the majority of DMOs (17 out of 24) with correlation coefficients meeting or exceeding the a priori hypotheses by clinical experts. All DMOs supported divergent validity. 22 out of 24 DMOs distinguished between disease severity groups successfully. Expert consensus supported construct validity of 17 DMOs. Conclusions: Construct validity was supported for all walking activity (amount and pattern) DMOs, and most of the gait (pace, rhythm, and bout-to-bout variability) DMOs, indicating the clinical utility of these measures., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking (JU) under grant agreement number 820820. This JU receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Content in this publication reflects the authors' view and neither IMI nor the European Union, EFPIA or any associated partners are responsible for any use that may be made of the information contained herein. Funding information for this article has been deposited with the Open Funder Registry.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Design and validation of a multi-task, multi-context protocol for real-world gait simulation

  • Scott, Kirsty
  • Koch, Sarah
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Mobilise-D consortium
Background: Measuring mobility in daily life entails dealing with confounding factors arising from multiple sources, including pathological characteristics, patient specific walking strategies, environment/context, and purpose of the task. The primary aim of this study is to propose and validate a protocol for simulating real-world gait accounting for all these factors within a single set of observations, while ensuring minimisation of participant burden and safety. Methods: The protocol included eight motor tasks at varying speed, incline/steps, surface, path shape, cognitive demand, and included postures that may abruptly alter the participants' strategy of walking. It was deployed in a convenience sample of 108 participants recruited from six cohorts that included older healthy adults (HA) and participants with potentially altered mobility due to Parkinson's disease (PD), multiple sclerosis (MS), proximal femoral fracture (PFF), chronic obstructive pulmonary disease (COPD) or congestive heart failure (CHF). A novelty introduced in the protocol was the tiered approach to increase difficulty both within the same task (e.g., by allowing use of aids or armrests) and across tasks. Results: The protocol proved to be safe and feasible (all participants could complete it and no adverse events were recorded) and the addition of the more complex tasks allowed a much greater spread in walking speeds to be achieved compared to standard straight walking trials. Furthermore, it allowed a representation of a variety of daily life relevant mobility aspects and can therefore be used for the validation of monitoring devices used in real life. Conclusions: The protocol allowed for measuring gait in a variety of pathological conditions suggests that it can also be used to detect changes in gait due to, for example, the onset or progression of a disease, or due to therapy. Trial registration: ISRCTN-12246987., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This study was also supported by the National Institute for Health Research (NIHR) through the Sheffield Biomedical Research Centre (BRC, Grant Number IS-BRC-1215–20017). AY, LA, LR and SDD are also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Center (BRC) based at Newcastle Upon Tyne Hospital NHS Foundation Trust and Newcastle University. AY, LA, LR and SDD are also supported by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), and from the Generalitat de Catalunya through the CERCA Program. All opinions are those of the authors and not the funders. Neither IMI nor the European Union, EFPIA, NHS, NIHR, DHSC or any Associated Partners are responsible for any use that may be made of the information contained herein.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A multi-sensor wearable system for the assessment of diseased gait in real-world conditions

  • Salis, Francesca
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Koch, Sarah
  • Mobilise-D consortium
Introduction: Accurately assessing people's gait, especially in real-world conditions and in case of impaired mobility, is still a challenge due to intrinsic and extrinsic factors resulting in gait complexity. To improve the estimation of gait-related digital mobility outcomes (DMOs) in real-world scenarios, this study presents a wearable multi-sensor system (INDIP), integrating complementary sensing approaches (two plantar pressure insoles, three inertial units and two distance sensors). Methods: The INDIP technical validity was assessed against stereophotogrammetry during a laboratory experimental protocol comprising structured tests (including continuous curvilinear and rectilinear walking and steps) and a simulation of daily-life activities (including intermittent gait and short walking bouts). To evaluate its performance on various gait patterns, data were collected on 128 participants from seven cohorts: healthy young and older adults, patients with Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary disease, congestive heart failure, and proximal femur fracture. Moreover, INDIP usability was evaluated by recording 2.5-h of real-world unsupervised activity. Results and discussion: Excellent absolute agreement (ICC >0.95) and very limited mean absolute errors were observed for all cohorts and digital mobility outcomes (cadence ≤0.61 steps/min, stride length ≤0.02 m, walking speed ≤0.02 m/s) in the structured tests. Larger, but limited, errors were observed during the daily-life simulation (cadence 2.72-4.87 steps/min, stride length 0.04-0.06 m, walking speed 0.03-0.05 m/s). Neither major technical nor usability issues were declared during the 2.5-h acquisitions. Therefore, the INDIP system can be considered a valid and feasible solution to collect reference data for analyzing gait in real-world conditions., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Content in this publication reflects the authors view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein. LA, SD, AY, and LR are also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at Newcastle Upon Tyne Hospital NHS Foundation Trust and Newcastle University. The work was also supported by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. All opinions are those of the authors and not the funders. A-EC, JG-A, and SK, all researchers from the Barcelona Institute for Global Health received support from the Spanish Ministry of Science, Innovation and Universities through the “Centro de Excelencia Severo Ochoa 2019–2023” Programme (CEX 2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Programme.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes

  • Polhemus, Ashley Marie
  • Delgado-Ortiz, Laura
  • Cardenas, Gabriela
  • Koch, Sarah
  • Bosch de Basea i Gómez, Magda, 1982-
  • García Aymerich, Judith
  • Mobilise-D
Physical mobility is essential to health, and patients often rate it as a high-priority clinical outcome. Digital mobility outcomes (DMOs), such as real-world gait speed or step count, show promise as clinical measures in many medical conditions. However, current research is nascent and fragmented by discipline. This scoping review maps existing evidence on the clinical utility of DMOs, identifying commonalities across traditional disciplinary divides. In November 2019, 11 databases were searched for records investigating the validity and responsiveness of 34 DMOs in four diverse medical conditions (Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary disease, hip fracture). Searches yielded 19,672 unique records. After screening, 855 records representing 775 studies were included and charted in systematic maps. Studies frequently investigated gait speed (70.4% of studies), step length (30.7%), cadence (21.4%), and daily step count (20.7%). They studied differences between healthy and pathological gait (36.4%), associations between DMOs and clinical measures (48.8%) or outcomes (4.3%), and responsiveness to interventions (26.8%). Gait speed, step length, cadence, step time and step count exhibited consistent evidence of validity and responsiveness in multiple conditions, although the evidence was inconsistent or lacking for other DMOs. If DMOs are to be adopted as mainstream tools, further work is needed to establish their predictive validity, responsiveness, and ecological validity. Cross-disciplinary efforts to align methodology and validate DMOs may facilitate their adoption into clinical practice., The Mobilise-D project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 820820. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This publication reflects the authors’ views and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein. H.D. is a postdoctoral research fellow of the FWO-Flanders. ISGlobal acknowledges support from the Spanish Ministry of Science, Innovation, and Universities through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The future of clinical trials? Monitoring mobility as an outcome measure in Parkinson's disease: The mobilise-D study.

  • Yarnall, Alison J.
  • Armengol, Claudia
  • Buekers, Joren
  • Delgado-Ortiz, Laura
  • García Aymerich, Judith
  • Koch, Sarah
BackgroundA key challenge in trials targeting disease modification in Parkinson's disease (PD) is the lack of sensitive, precise, and patient-relevant outcome measures. Digital mobility outcomes (DMOs), captured using body-worn devices, offer a novel, objective means to assess real-world gait and mobility-domains often impaired early in PD. The Mobilise-D consortium was established to develop and validate DMOs in PD and other conditions.ObjectiveTo describe DMOs in a large, representative international cohort of individuals with PD and compare to controls and across disease stage; and to determine compliance and feasibility.MethodsAs part of the Mobilise-D Clinical Validation and Extension Studies, real-world mobility of individuals with PD (n = 601) and matched controls (n = 232) was assessed using a single wearable device for seven days. Data were processed to yield 24 technically validated DMOs, representing different domains of real-world walking and mobility performance.ResultsDMO data were available for 531 PD and 221 controls. Significant differences between the groups were observed in 20 of 24 DMOs. Compared to controls, PD participants exhibited shorter daily walking duration and lower step counts, walking at a higher cadence and in fewer walking bouts per day. Findings also varied by disease severity, with differences observed particularly between controls vs. mild (Hoehn and Yahr stage I-II) and mild vs. moderate (Hoehn and Yahr stage III) disease. Compliance rates were high.ConclusionsDistinct DMO patterns across PD severity and between PD and controls support their utility as sensitive, scalable outcome measures for future clinical trials and therapeutic development., The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Mobilise-D project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 820820. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This publication reflects the author's views and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the nformation contained herein. The Mobilise-D Extension study was funded by the Michael J Fox Foundation (MJFF-022735).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Investigating the prognostic value of digital mobility outcomes in patients with chronic obstructive pulmonary disease: a systematic literature review and meta-analysis

  • Buttery, Sara C.
  • Buekers, Joren
  • Delgado-Ortiz, Laura
  • García Aymerich, Judith
  • Gimeno Santos, Elena, 1980-
  • Koch, Sarah
  • Hopkinson, Nicholas S.
Background: Reduced mobility is a central feature of COPD. Assessment of mobility outcomes that can be measured digitally (digital mobility outcomes (DMOs)) in daily life such as gait speed and steps per day is increasingly possible using devices such as pedometers and accelerometers, but the predictive value of these measures remains unclear in relation to key outcomes such as hospital admission and survival. Methods: We conducted a systematic review, nested within a larger scoping review by the MOBILISE-D consortium, addressing DMOs in a range of chronic conditions. Qualitative and quantitative analysis considering steps per day and gait speed and their association with clinical outcomes in COPD patients was performed. Results: 21 studies (6076 participants) were included. Nine studies evaluated steps per day and 11 evaluated a measure reflecting gait speed in daily life. Negative associations were demonstrated between mortality risk and steps per day (per 1000 steps) (hazard ratio (HR) 0.81, 95% CI 0.75-0.88, p<0.001), gait speed (<0.80 m·s-1) (HR 3.55, 95% CI 1.72-7.36, p<0.001) and gait speed (per 1.0 m·s-1) (HR 7.55, 95% CI 1.11-51.3, p=0.04). Fewer steps per day (per 1000) and slow gait speed (<0.80 m·s-1) were also associated with increased healthcare utilisation (HR 0.80, 95% CI 0.72-0.88, p<0.001; OR 3.36, 95% CI 1.42-7.94, p=0.01, respectively). Available evidence was of low-moderate quality with few studies eligible for meta-analysis. Conclusion: Daily step count and gait speed are negatively associated with mortality risk and other important outcomes in people with COPD and therefore may have value as prognostic indicators in clinical trials, but the quantity and quality of evidence is limited. Larger studies with consistent methodologies are called for., This work was supported by the Mobilise-D project; the Mobilise-D project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 820820. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This publication reflects the authors’ views and neither IMI nor the European Union, EFPIA or any Associated Partners are responsible for any use that may be made of the information contained herein. H. Demeyer is a postdoctoral research fellow of the FWO-Flanders. ISGlobal acknowledges support from the grant CEX2018–000806-S funded by MCIN/AEI/ 10.13039/501100011033, and the Generalitat de Catalunya through the CERCA Program and L. Delgado-Ortiz is funded by the following grant: Contratos Predoctorales de Formación en Investigación en Salud (PFIS) 2021 of the AES with Exp. FI21/00113 from ISCIII, and the European Social Fund Plus (ESF+). This research was supported by the NIHR Imperial Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care, the IMI, the European Union, the EFPIA or any Associated Partners. Funding information for this article has been deposited with the Crossref Funder Registry.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Aging towards walkable futures: insights from a multidisciplinary workshop held in Barcelona, Spain

  • Vall Garcia, Enric
  • Delgado-Ortiz, Laura
  • Alcock, Lisa
  • Coll Planas, Laura
  • Garcia-Navarro, Jose Augusto
  • Iwarsson, Susanne
  • Jansà, Josep Maria
  • Jansen, Carl-Philipp
  • Koch, Sarah
  • Schwartz, Simon
  • Rantakokko, Merja
  • Sarukhan, Adelaida
  • van Staalduinen, Willeke
  • Rochester, Lynn
  • García Aymerich, Judith
Background: The aging of the world's population and the increase in sedentary lifestyles are leading to an increase in walking impairments at older ages. Here, we aimed to comprehensively discuss walking in the context of an aging population; and identify and agree on a list of future research priorities and policy actions. Methods: We followed a participatory approach and held a multidisciplinary two-day workshop on October, 2023 in Barcelona, Spain, with experts in the fields of aging and walking, and participants from the general public. Results: A total of 56 national and international participants, from a multidisciplinary background, joined the workshop. They had a median age of 40 years (range 24-83), and 62% were female. Participants discussed the meaning of walking from different perspectives and its change with age and in the presence of diverse mobility-impairing conditions; the emotional and social components of walking; and the role of the environment in walking. Participants identified unmet needs, research priorities and policy actions related to walking in older ages. Conclusions: This two-day workshop provided a space for professionals and public to comprehensively discuss walking at older ages. Participants highlighted the relevance of a better and more comprehensive assessment of walking; the need to shift focus towards comprehensive health that considers physical, emotional and social aspects as well as individuals' preferences and expectations; and the importance of translating research into action. Future work can draw on the discussions held during this event in a thought-provoking and hypothesis-generating way., ISGlobal acknowledges support from the grant CEX2018-000806-S funded by MCIN/AEI/https://doi.org/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Programme. This work was also supported by the Severo-Ochoa program at ISGlobal and the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The content of the current publication reflects the authors’ view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein. LD-O receives funding from the grant “Contratos Predoctorales de Formación en Investigación en Salud (PFIS) 2021 of the AES with Exp. FI21/00113” from ISCIII, and the European Social Fund Plus (ESF+). LR acknowledges infrastructure support provided by Newcastle Biomedical Research Centre (BRC) hosted by Newcastle upon Tyne Hospitals National Health Service (NHS) Foundation Trust and Newcastle University, UK.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Real-World gait detection using a wrist-worn inertial sensor: Validation study

  • Kluge, Felix
  • Buekers, Joren
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Koch, Sarah
  • Mueller, Arne
Background: Wrist-worn inertial sensors are used in digital health for evaluating mobility in real-world environments. Preceding the estimation of spatiotemporal gait parameters within long-term recordings, gait detection is an important step to identify regions of interest where gait occurs, which requires robust algorithms due to the complexity of arm movements. While algorithms exist for other sensor positions, a comparative validation of algorithms applied to the wrist position on real-world data sets across different disease populations is missing. Furthermore, gait detection performance differences between the wrist and lower back position have not yet been explored but could yield valuable information regarding sensor position choice in clinical studies. Objective: The aim of this study was to validate gait sequence (GS) detection algorithms developed for the wrist position against reference data acquired in a real-world context. In addition, this study aimed to compare the performance of algorithms applied to the wrist position to those applied to lower back-worn inertial sensors. Methods: Participants with Parkinson disease, multiple sclerosis, proximal femoral fracture (hip fracture recovery), chronic obstructive pulmonary disease, and congestive heart failure and healthy older adults (N=83) were monitored for 2.5 hours in the real-world using inertial sensors on the wrist, lower back, and feet including pressure insoles and infrared distance sensors as reference. In total, 10 algorithms for wrist-based gait detection were validated against a multisensor reference system and compared to gait detection performance using lower back-worn inertial sensors. Results: The best-performing GS detection algorithm for the wrist showed a mean (per disease group) sensitivity ranging between 0.55 (SD 0.29) and 0.81 (SD 0.09) and a mean (per disease group) specificity ranging between 0.95 (SD 0.06) and 0.98 (SD 0.02). The mean relative absolute error of estimated walking time ranged between 8.9% (SD 7.1%) and 32.7% (SD 19.2%) per disease group for this algorithm as compared to the reference system. Gait detection performance from the best algorithm applied to the wrist inertial sensors was lower than for the best algorithms applied to the lower back, which yielded mean sensitivity between 0.71 (SD 0.12) and 0.91 (SD 0.04), mean specificity between 0.96 (SD 0.03) and 0.99 (SD 0.01), and a mean relative absolute error of estimated walking time between 6.3% (SD 5.4%) and 23.5% (SD 13%). Performance was lower in disease groups with major gait impairments (eg, patients recovering from hip fracture) and for patients using bilateral walking aids. Conclusions: Algorithms applied to the wrist position can detect GSs with high performance in real-world environments. Those periods of interest in real-world recordings can facilitate gait parameter extraction and allow the quantification of gait duration distribution in everyday life. Our findings allow taking informed decisions on alternative positions for gait recording in clinical studies and public health. Trial registration: ISRCTN Registry 12246987; https://www.isrctn.com/ISRCTN12246987. International registered report identifier (irrid): RR2-10.1136/bmjopen-2021-050785., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU; grant 820820). The IMI2 JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations. SDD, LR, and AY were also supported by the IMI2 JU project Identifying Digital Endpoints to Assess Fatigue, Sleep and Activities in Daily Living (grant 853981). LA, LR, AY, and SDD were also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear NHS Foundation Trust. JMH and YEB are supported in part by the National Institutes of Health (grant R01AG79133). LA, LR, AY, and SDD were also supported by the NIHR/Wellcome Trust Clinical Research Facility infrastructure at The Newcastle upon Tyne Hospitals NHS Foundation Trust. This study was also supported by the NIHR through the Sheffield BRC (grant IS-BRC-1215-20017). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” program (CEX2018-000806-S) and from the Generalitat de Catalunya through the Centres de Recerca de Catalunya program. All opinions are those of the authors and not the funders. The content in this publication reflects the authors’ view, and neither Innovative Medicines Initiative nor the European Union, European Federation of Pharmaceutical Industries and Associations, National Health Service, NIHR, Department of Health and Social Care, or any associated partners are responsible for any use that may be made of the information contained herein.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Ecological validity of a deep learning algorithm to detect gait events from real-life walking bouts in mobility-limiting diseases

  • Romijnders, Robbin
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Koch, Sarah
  • Maetzler, Walter
Introduction: The clinical assessment of mobility, and walking specifically, is still mainly based on functional tests that lack ecological validity. Thanks to inertial measurement units (IMUs), gait analysis is shifting to unsupervised monitoring in naturalistic and unconstrained settings. However, the extraction of clinically relevant gait parameters from IMU data often depends on heuristics-based algorithms that rely on empirically determined thresholds. These were mainly validated on small cohorts in supervised settings. Methods: Here, a deep learning (DL) algorithm was developed and validated for gait event detection in a heterogeneous population of different mobility-limiting disease cohorts and a cohort of healthy adults. Participants wore pressure insoles and IMUs on both feet for 2.5 h in their habitual environment. The raw accelerometer and gyroscope data from both feet were used as input to a deep convolutional neural network, while reference timings for gait events were based on the combined IMU and pressure insoles data. Results and discussion: The results showed a high-detection performance for initial contacts (ICs) (recall: 98%, precision: 96%) and final contacts (FCs) (recall: 99%, precision: 94%) and a maximum median time error of -0.02 s for ICs and 0.03 s for FCs. Subsequently derived temporal gait parameters were in good agreement with a pressure insoles-based reference with a maximum mean difference of 0.07, -0.07, and <0.01 s for stance, swing, and stride time, respectively. Thus, the DL algorithm is considered successful in detecting gait events in ecologically valid environments across different mobility-limiting diseases., This study was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). LA, LR, AY, and SD were also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at Newcastle upon Tyne Hospital NHS Foundation Trust and Newcastle University and the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon the Tyne Hospitals NHS Foundation Trust. This study was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) through the project B9 of the Collaborative Research Centre CRC 1261 Magnetoelectric Sensors: From Composite Materials to Biomagnetic Diagnostics.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

On the use of wearable sensors as mobility biomarkers in the marketing authorization of new drugs: A regulatory perspective

  • Viceconti, Marco
  • Tome, Maria
  • Dartee, Wilhelmus
  • Knezevic, Igor
  • Hernandez Penna, Sabina
  • Mazzà, Claudia
  • Caulfield, Brian
  • García Aymerich, Judith
  • Becker, Clemens
  • Maetzler, Walter
  • Troosters, Thierry
  • Sharrack, Basil
  • Davico, Giorgio
  • Corriol-Rohou, Solange
  • Rochester, Lynn
  • Mobilise-D consortium
The loss of mobility is a common trait in multiple health conditions (e.g., Parkinson's disease) and is associated with reduced quality of life. In this context, being able to monitor mobility in the real world, is important. Until recently, the technology was not mature enough for this; but today, miniaturized sensors and novel algorithms promise to monitor mobility accurately and continuously in the real world, also in pathological populations. However, before any such methodology can be employed to support the development and testing of new drugs in clinical trials, they need to be qualified by the competent regulatory agencies (e.g., European Medicines Agency). Nonetheless, to date, only very narrow scoped requests for regulatory qualification were successful. In this work, the Mobilise-D Consortium shares its positive experience with the European regulator, summarizing the two requests for Qualification Advice for the Mobilise-D methodologies submitted in October 2019 and June 2020, as well as the feedback received, which resulted in two Letters of Support publicly available for consultation on the website of the European Medicines Agency. Leveraging on this experience, we hereby propose a refined qualification strategy for the use of digital mobility outcome (DMO) measures as monitoring biomarkers for mobility in drug trials., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Content in this publication reflects the authors' view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein. CM was supported by the NIHR Sheffield Biomedical Research Center (BRC).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

How do people with COPD walk? A European study on digitally measured real-world gait

  • Delgado-Ortiz, Laura
  • Buekers, Joren
  • Gimeno Santos, Elena, 1980-
  • Koch, Sarah
  • García Aymerich, Judith
Background: The amount of walking that people with COPD do is reduced. However, data on their manner of walking (i.e. gait) are still lacking. We characterised real-world gait in COPD by assessing levels and distributions of gait parameters, and comparing them across COPD severity and with healthy peers. Methods: 549 people with COPD from seven European sites and 19 healthy older adults wore single wearable devices (either Axivity AX6 or DynaPort MoveMonitor MM+) continuously for 1 week, from which we identified walking bouts, calculated 15 digital mobility outcomes (DMOs) aggregated at the weekly level, and compared them across COPD severity levels and with healthy peers. Results: Of the participants with COPD, 37% were female with a mean±sd age of 68±8 years and a post-bronchodilator forced expiratory volume in 1 s of 54±20% predicted. All gait DMOs were normally distributed and exhibited variability between participants (e.g. mean±sd walking speed of 0.83±0.12 m·s-1, ranging from 0.48 to 1.20 m·s-1). Walking speed and cadence DMOs were lower with increasing disease severity (e.g. mean±sd walking speed of 0.88±0.11, 0.85±0.12, 0.80±0.12 and 0.78±0.14 m·s-1 across Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades 1 to 4, p<0.001; mean±sd cadence of 93±6, 91±6 and 89±7 steps·min-1 across GOLD A, B and E, p=0.013). Stride length and duration varied across COPD severity levels. Walking speed and cadence bout-to-bout variability only varied across dyspnoea severity levels. In a secondary analysis, we compared DMO data from people with COPD to a convenience sample of 19 healthy older adults (47% women, mean age 71±6 years) and found that walking speed and cadence varied between participants with COPD and healthy adults (e.g. mean±sd walking speed 0.83±0.12 versus 0.90±0.12 m·s-1, p=0.041). Conclusion: In people with COPD, gait DMOs are normally distributed and worsen as disease advances. Moreover, walking speed and cadence DMOs are significantly altered when compared to healthy peers. Further research should elucidate which DMOs can be improved with treatments to enhance mobility and reduce adverse events., This work was supported by the Mobilise-D project that has received funding from the IMI2 JU under grant agreement number 820820. This JU receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The content of the current publication reflects the authors’ view and neither IMI nor the European Union, EFPIA or any associated partners are responsible for any use that may be made of the information contained herein. ISGlobal acknowledges support from the grant CEX2023-0001290-S funded by CIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Programme. L. Delgado-Ortiz received funding from the grant “Contratos Predoctorales de Formación en Investigación en Salud (PFIS) 2021 of the AES with Exp. FI21/00113” from Instituto de Salud Carlos III, and the European Social Fund Plus. L. Rochester and S. Del Din were supported by the NIHR Newcastle BRC based at Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and Cumbria, Northumberland and Tyne and Wear NHS Foundation Trust. H. Demeyer is a post-doctoral fellow of FWO Flanders (12ZW822N). S. Koch received funding from the Juan de la Cierva Incorporación Fellowship of the Spanish Ministry of Research and Innovation (IJC2020-044363-I). J. Buekers received funding from the grant “FJC2021-046458-I” financed by MICIU/AEI/10.13039/501100011033 and by the European Union NextGeneration EU/PRTR. Funding Information for this article has been deposited with the Crossref Funder Registry.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

On the use of wearable sensors as mobility biomarkers in the marketing authorization of new drugs: A regulatory perspective

  • Viceconti, Marco
  • Tome, Maria
  • Dartee, Wilhelmus
  • Knezevic, Igor
  • Hernandez Penna, Sabina
  • Mazzà, Claudia
  • Caulfield, Brian
  • García Aymerich, Judith
  • Becker, Clemens
  • Maetzler, Walter
  • Troosters, Thierry
  • Sharrack, Basil
  • Davico, Giorgio
  • Corriol-Rohou, Solange
  • Rochester, Lynn
  • Mobilise-D consortium
The loss of mobility is a common trait in multiple health conditions (e.g., Parkinson's disease) and is associated with reduced quality of life. In this context, being able to monitor mobility in the real world, is important. Until recently, the technology was not mature enough for this; but today, miniaturized sensors and novel algorithms promise to monitor mobility accurately and continuously in the real world, also in pathological populations. However, before any such methodology can be employed to support the development and testing of new drugs in clinical trials, they need to be qualified by the competent regulatory agencies (e.g., European Medicines Agency). Nonetheless, to date, only very narrow scoped requests for regulatory qualification were successful. In this work, the Mobilise-D Consortium shares its positive experience with the European regulator, summarizing the two requests for Qualification Advice for the Mobilise-D methodologies submitted in October 2019 and June 2020, as well as the feedback received, which resulted in two Letters of Support publicly available for consultation on the website of the European Medicines Agency. Leveraging on this experience, we hereby propose a refined qualification strategy for the use of digital mobility outcome (DMO) measures as monitoring biomarkers for mobility in drug trials., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Content in this publication reflects the authors' view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein. CM was supported by the NIHR Sheffield Biomedical Research Center (BRC).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The future of clinical trials? Monitoring mobility as an outcome measure in Parkinson's disease: The mobilise-D study.

  • Yarnall, Alison J.
  • Armengol, Claudia
  • Buekers, Joren
  • Delgado-Ortiz, Laura
  • García Aymerich, Judith
  • Koch, Sarah
BackgroundA key challenge in trials targeting disease modification in Parkinson's disease (PD) is the lack of sensitive, precise, and patient-relevant outcome measures. Digital mobility outcomes (DMOs), captured using body-worn devices, offer a novel, objective means to assess real-world gait and mobility-domains often impaired early in PD. The Mobilise-D consortium was established to develop and validate DMOs in PD and other conditions.ObjectiveTo describe DMOs in a large, representative international cohort of individuals with PD and compare to controls and across disease stage; and to determine compliance and feasibility.MethodsAs part of the Mobilise-D Clinical Validation and Extension Studies, real-world mobility of individuals with PD (n = 601) and matched controls (n = 232) was assessed using a single wearable device for seven days. Data were processed to yield 24 technically validated DMOs, representing different domains of real-world walking and mobility performance.ResultsDMO data were available for 531 PD and 221 controls. Significant differences between the groups were observed in 20 of 24 DMOs. Compared to controls, PD participants exhibited shorter daily walking duration and lower step counts, walking at a higher cadence and in fewer walking bouts per day. Findings also varied by disease severity, with differences observed particularly between controls vs. mild (Hoehn and Yahr stage I-II) and mild vs. moderate (Hoehn and Yahr stage III) disease. Compliance rates were high.ConclusionsDistinct DMO patterns across PD severity and between PD and controls support their utility as sensitive, scalable outcome measures for future clinical trials and therapeutic development., The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Mobilise-D project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 820820. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This publication reflects the author's views and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the nformation contained herein. The Mobilise-D Extension study was funded by the Michael J Fox Foundation (MJFF-022735).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Toward a regulatory qualification of real-world mobility performance biomarkers in parkinson's patients using digital mobility outcomes

  • Viceconti, Marco
  • Hernández Penna, Sabina
  • Dartee, Wilhelmus
  • Mazzà, Claudia
  • Caulfield, Brian
  • Becker, Clemens
  • Maetzler, Walter
  • García Aymerich, Judith
  • Davico, Giorgio
  • Rochester, Lynn
Wearable inertial sensors can be used to monitor mobility in real-world settings over extended periods. Although these technologies are widely used in human movement research, they have not yet been qualified by drug regulatory agencies for their use in regulatory drug trials. This is because the first generation of these sensors was unreliable when used on slow-walking subjects. However, intense research in this area is now offering a new generation of algorithms to quantify Digital Mobility Outcomes so accurate they may be considered as biomarkers in regulatory drug trials. This perspective paper summarises the work in the Mobilise-D consortium around the regulatory qualification of the use of wearable sensors to quantify real-world mobility performance in patients affected by Parkinson's Disease. The paper describes the qualification strategy and both the technical and clinical validation plans, which have recently received highly supportive qualification advice from the European Medicines Agency. The scope is to provide detailed guidance for the preparation of similar qualification submissions to broaden the use of real-world mobility assessment in regulatory drug trials., This study was supported by the project Mobilise-D, “Digital sensors to monitor mobility, disease progression”, Grant agreement ID: 820820, funded by the European Commission through the programme H2020-EU.3.1.7.-Innovative Medicines Initiative 2 (IMI2). Author JGA also acknowledge support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Can digital mobility assessment enhance the clinical assessment of disease severity in Parkinson's disease?

  • Kirk, Cameron
  • Rehman, Rana Zia Ur
  • Galna, Brook
  • Alcock, Lisa
  • Ranciati, Saverio
  • Palmerini, Luca
  • García Aymerich, Judith
  • Hansen, Clint
  • Schaeffer, Eva
  • Berg, Daniela
  • Maetzler, Walter
  • Rochester, Lynn
  • Del Din, Silvia
  • Yarnall, Alison J.
Background: Real-world walking speed (RWS) measured using wearable devices has the potential to complement the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS III) for motor assessment in Parkinson's disease (PD). Objective: Explore cross-sectional and longitudinal differences in RWS between PD and older adults (OAs), and whether RWS was related to motor disease severity cross-sectionally, and if MDS-UPDRS III was related to RWS, longitudinally. Methods: 88 PD and 111 OA participants from ICICLE-GAIT (UK) were included. RWS was evaluated using an accelerometer at four time points. RWS was aggregated within walking bout (WB) duration thresholds. Between-group-comparisons in RWS between PD and OAs were conducted cross-sectionally, and longitudinally with mixed effects models (MEMs). Cross-sectional association between RWS and MDS-UPDRS III was explored using linear regression, and longitudinal association explored with MEMs. Results: RWS was significantly lower in PD (1.04 m/s) in comparison to OAs (1.10 m/s) cross-sectionally. RWS significantly decreased over time for both cohorts and decline was more rapid in PD by 0.02 m/s per year. Significant negative relationship between RWS and the MDS-UPDRS III only existed at a specific WB threshold (30 to 60 s, β= - 3.94 points, p = 0.047). MDS-UPDRS III increased significantly by 1.84 points per year, which was not related to change in RWS. Conclusion: Digital mobility assessment of gait may add unique information to quantify disease progression remotely, but further validation in research and clinical settings is needed., This work is also supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) project Mobilise-D that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Content in this publication reflects the authors’ view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Digital mobility outcomes to describe real-world walking during recovery from a hip fracture: the Mobilise-D perspective

  • Becker, Clemens
  • García Aymerich, Judith
  • Delgado-Ortiz, Laura
  • Koch, Sarah
  • Buekers, Joren
  • Alvarez, Paula
  • Marcuzzi, Anna
Purpose: The burden of disease caused by fragility fractures, and hip fractures in particular, is significant both from a personal and a societal perspective. Digital technologies such as wearable devices now allow a real-world assessment of walking and physical mobility, describing temporal and spatial measures. Built on a transparent technical validation, the Mobilise-D consortium validated a set of digital mobility outcomes (DMOs) alongside a longitudinal clinical validation study (CVS). This article provides a description of DMOs along with supervised mobility assessment and patient-reported outcomes collected at entry of the CVS study in a sample of home-dwelling participants with a proximal femoral fracture (PFF) recruited within 1 year after surgery. Methods: Participants who underwent surgical treatment for a low-energy PFF were recruited from five sites in three high-income European countries. The first visit encompassed a clinical assessment (~ 3 h) and subsequent 7-day measurement of real-world mobility with a single wearable device. We categorized participants into four recovery phases according to the assessment time after surgery: acute phase (≤ 14 days after surgery, hospital stay), post-acute phase (15-42 days after surgery, mostly rehabilitation), extended recovery phase (43-182 days post-surgery, typically post-discharge at home), and long-term recovery phase (183-365 days post-surgery). All variables were reported descriptively for each phase using mean and standard deviation or median and 25th-75th percentile depending on their distribution. Results: We enrolled 564 PFF participants (66% women). The mean age was 77.5 (SD 9.6) years. Almost 90% of all participants (n = 505) had a valid digital mobility assessment (wear time of > 12 h per day and at least 3 valid days). DMO domains such as amount (e.g., number of steps), pace (e.g., walking speed), and pattern (bout distribution) demonstrated large differences across phases. Conclusions: The observed variation in walking amount and pace and pattern across recovery phases indicate that DMOs provide a granular analysis of real-world mobility of hip fracture survivors. When confirmed by longitudinal analyses, including results on minimal important differences, the use of selected DMOs will provide a novel approach for monitoring, predictive modelling, prognosis, stratification, and evaluation of clinical trials and hip fracture services., Open Access funding enabled and organized by Projekt DEAL. This study was part of the Mobilise-D project, which was funded by the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). SDD and LR were also supported by the IDEA-FAST project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 853981.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A multi-sensor wearable system for the assessment of diseased gait in real-world conditions

  • Salis, Francesca
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Koch, Sarah
  • Mobilise-D consortium
Introduction: Accurately assessing people's gait, especially in real-world conditions and in case of impaired mobility, is still a challenge due to intrinsic and extrinsic factors resulting in gait complexity. To improve the estimation of gait-related digital mobility outcomes (DMOs) in real-world scenarios, this study presents a wearable multi-sensor system (INDIP), integrating complementary sensing approaches (two plantar pressure insoles, three inertial units and two distance sensors). Methods: The INDIP technical validity was assessed against stereophotogrammetry during a laboratory experimental protocol comprising structured tests (including continuous curvilinear and rectilinear walking and steps) and a simulation of daily-life activities (including intermittent gait and short walking bouts). To evaluate its performance on various gait patterns, data were collected on 128 participants from seven cohorts: healthy young and older adults, patients with Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary disease, congestive heart failure, and proximal femur fracture. Moreover, INDIP usability was evaluated by recording 2.5-h of real-world unsupervised activity. Results and discussion: Excellent absolute agreement (ICC >0.95) and very limited mean absolute errors were observed for all cohorts and digital mobility outcomes (cadence ≤0.61 steps/min, stride length ≤0.02 m, walking speed ≤0.02 m/s) in the structured tests. Larger, but limited, errors were observed during the daily-life simulation (cadence 2.72-4.87 steps/min, stride length 0.04-0.06 m, walking speed 0.03-0.05 m/s). Neither major technical nor usability issues were declared during the 2.5-h acquisitions. Therefore, the INDIP system can be considered a valid and feasible solution to collect reference data for analyzing gait in real-world conditions., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Content in this publication reflects the authors view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein. LA, SD, AY, and LR are also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at Newcastle Upon Tyne Hospital NHS Foundation Trust and Newcastle University. The work was also supported by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. All opinions are those of the authors and not the funders. A-EC, JG-A, and SK, all researchers from the Barcelona Institute for Global Health received support from the Spanish Ministry of Science, Innovation and Universities through the “Centro de Excelencia Severo Ochoa 2019–2023” Programme (CEX 2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Programme.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving?

  • Jaeger, Simon U.
  • Wohlrab, Martin
  • Schoene, Daniel
  • Tremmel, Roman
  • Chambers, Michael
  • Leocani, Letizia
  • Corriol-Rohou, Solange
  • Klenk, Jochen
  • Sharrack, Basil
  • García Aymerich, Judith
  • Rochester, Lynn
  • Maetzler, Walter
  • Puhan, Milo A.
  • Schwab, Matthias
  • Becker, Clemens
Background: Mobility is defined as the ability to independently move around the environment and is a key contributor to quality of life, especially in older age. The aim of this study was to evaluate the use of mobility as a decisive outcome for the marketing authorisation of drugs by the European Medicines Agency (EMA). Methods: Fifteen therapeutic areas which commonly lead to relevant mobility impairments and alter the quantity and/or the quality of walking were selected: two systemic neurological diseases, four conditions primarily affecting exercise capacity, seven musculoskeletal diseases and two conditions representing sensory impairments. European Public Assessment Reports (EPARs) published by the EMA until September 2020 were examined for mobility endpoints included in their 'main studies'. Clinical study registries and primary scientific publications for these studies were also reviewed. Results: Four hundred and eighty-four EPARs yielded 186 relevant documents with 402 'main studies'. The EPARs reported 153 primary and 584 secondary endpoints which considered mobility; 70 different assessment tools (38 patient-reported outcomes, 13 clinician-reported outcomes, 8 performance outcomes and 13 composite endpoints) were used. Only 15.7% of those tools distinctly informed on patients' mobility status. Out of 402, 105 (26.1%) of the 'main studies' did not have any mobility assessment. Furthermore, none of these studies included a digital mobility outcome. Conclusions: For conditions with a high impact on mobility, mobility assessment was given little consideration in the marketing authorisation of drugs by the EMA. Where mobility impairment was considered to be a relevant outcome, questionnaires or composite scores susceptible to reporting biases were predominantly used., S.J., M.W., and R.T. are partly supported by the Robert Bosch Stiftung Stuttgart. M.W. reports grants from HORIZON2020 IMI No. 820820, during the conduct of the study. D.S. reports grants from HORIZON2020 IMI No. 820820, during the conduct of the study. M.C. reports personal fees from Takeda Pharmaceuticals, during the conduct of the study; personal fees from Takeda Pharmaceuticals, outside the submitted work. J.K. reports grants from HORIZON2020 IMI No. 820820, during the conduct of the study. J.G.A. reports grants from HORIZON2020 IMI No. 820820, and from AstraZeneca, Chiesi, Esteve, outside the submitted work. W.M. receives or received funding from the European Union, the German Federal Ministry of Education of Research, Michael J. Fox Foundation, Robert Bosch Foundation, Neuroalliance, Lundbeck and Janssen. He received speaker honoraria from Abbvie, Bayer, GlaxoSmithKline, Licher MT, Rölke Pharma and UCB, was invited to Advisory Boards of Abbvie, Biogen, Lundbeck and Market Access & Pricing Strategy GmbH, and is an advisory board member of the Critical Path for Parkinson’s Consortium. He serves as the co-chair of the MDS Technology Task Force. M.P. reports grants from HORIZON2020 IMI No. 820820, outside the submitted work. M.S. is supported by the Robert Bosch Stiftung Stuttgart and reports grants from HORIZON2020 IMI 2 Mobilise D, during the conduct of the study, and grants and non-financial support from Green Cross WellBeing Co. Ltd., Gilead Sciences Inc., Robert Bosch GmbH, and CORAT Therapeutics GmbH, as well as other from Agena Bioscience GmbH, outside the submitted work. C.B. disclosed consultation from E. Lilly and speaker fees from Amgen, Nutricia and Pfizer reports grants from HORIZON2020 IMI No. 820820, during the conduct of the study.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cocreating the visualization of digital mobility outcomes: Delphi-type process with patients

  • Lumsdon, Jack
  • Delgado-Ortiz, Laura
  • García Aymerich, Judith
  • Cantu, Alma
Background: Recent technological advances in wearable devices offer new potential for measuring mobility in real-world contexts. Mobilise-D has validated digital mobility outcomes to provide novel outcomes and end points in clinical research of 4 different long-term health conditions (Parkinson disease, multiple sclerosis, chronic obstructive pulmonary disease, and proximal femoral fracture). These outcomes also provide unique information that is important to patients; however, there is limited literature that explores the optimal methods to achieve this, such as the best way to visualize patients' data. Objective: This study aimed to identify meaningful outcomes for each condition and how to best visualize them from the perspective of end users. Methods: Using a Delphi-type protocol with patients as subject matter experts, we gathered iterative feedback on the cocreation of visualizations through 3 rounds of questionnaires. An open-ended questionnaire was used in round 1 to understand what aspects of mobility were most influenced by their health condition. These responses were mapped onto relevant digital mobility outcomes and walking experiences and then prioritized for visualization. Using patient responses, we worked alongside researchers, clinicians, and a patient advisory group to develop visualizations that depicted a week of mobility data. During rounds 2 and 3, participants rated usefulness and ease of understanding on a 5-point Likert scale and provided unstructured feedback in comment boxes for each visualization. Visualizations were refined using the feedback from round 2 before receiving further feedback in round 3. Results: Participation varied across rounds 1 to 3 (n=48, n=79, and n=78, respectively). Round 1 identified important outcomes and contexts for each health condition, such as walking speed and stride length for people with Parkinson disease or multiple sclerosis and number of steps for people with chronic obstructive pulmonary disease or proximal femoral fracture. The consensus was not reached for any visualization reviewed in round 2 or 3. Feedback was generally positive, and some participants reported that they were able to understand the visualization and interpret what the visualization represented. Conclusions: Through the feedback provided and existing data visualization principles, we developed recommendations for future visualizations of mobility- and health-related data. Visualizations should be readable by ensuring that large and clear fonts are used and should be friendly for people with vision impairments, such as color blindness. Patients have a strong understanding of their own condition and its variability; hence, adding additional factors into visualizations is recommended to better reflect the nuances of a condition. Ensuring that outcomes and visualizations are meaningful requires close collaboration with patients throughout the development process., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking (JU; grant agreement 820820). This JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The content of the current publication reflects the authors’ view, and neither IMI nor the European Union, EFPIA, nor any associated partners are responsible for any use that may be made of the information contained herein. HG was supported by the Fraunhofer Internal Programs (grants Attract 044–602140 and 044–602150). HG also received institutional funding from the Deutsche Forschungsgemeinschaft (German Research Foundation)—SFB 1483—Project-ID 442419336, EmpkinS. LR, AY, and SDD were also supported by the IMI2 JU project IDEA-FAST (grant agreement 853981). LR, AY, and SDD were supported by the National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre based at The Newcastle upon Tyne Hospital National Health Service (NHS) Foundation Trust, Newcastle University, and the Cumbria, Northumberland, and Tyne and Wear NHS Foundation Trust and the NIHR/Wellcome Trust Clinical Research Facility infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. LR received funding from the NIHR Senior Investigator Awards (2020-2024 and 2024-2028). EB was supported by the NIHR Sheffield Biomedical-Research Centre and Clinical Research Facility. The views expressed are those of the authors and not necessarily those of the NHS, NIHR, or the Department of Health and Social Care.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Construct validity of real-world digital mobility outcomes in patients after proximal femoral fracture: a cross-sectional observational study

  • Eckert, Tobias
  • de las Heras, Martí
  • Alvarez, Paula
  • Buekers, Joren
  • Koch, Sarah
  • García Aymerich, Judith
Digital mobility outcomes (DMOs) offer unique insights into recovery of real-world mobility after proximal femoral fracture (PFF), but their clinical validity remains to be established. This study assessed construct validity (convergent, divergent, and known-groups) of 24 DMOs measuring walking activity (amount, pattern) and gait (pace, rhythm, bout-to-bout variability) in patients within one year after PFF. Patients were recruited from inpatient and outpatient lists at five European sites, resulting in 505 included participants (66% female), with mean age of 77.6 ± 9.4 years and supervised gait speed of 0.7 ± 0.4 m/s. Mobility was monitored over seven days using a single wearable device on the lower back. Convergent and divergent validity analyses were stratified by two groups: acute (≤ 14 days since surgery) and non-acute (≥ 15 days since surgery). Correlations between DMOs and related (clinical- and patient-reported mobility outcomes) and unrelated constructs (hearing impairment and systolic blood pressure) were compared to a priori expected correlations. Known-groups validity was assessed across four recovery phases. The results were evaluated individually by experts and in a subsequent consensus meeting, with 17 of 24 DMOs showing evidence of construct validity in non-acute PFF patients. These findings represent an initial step in a larger process towards regulatory endorsement., This study is part of the Mobilise-D project, which was funded by the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU received support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This work was also supported by the National Institute for Health and Care Research (NIHR) Sheffield Biomedical Research Centre (NIHR203321). ISGlobal acknowledges support from the grant CEX2023-0001290-S funded by MCIN/AEI/ https://doi.org/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. MdlH was funded by European Union-NextGenerationEU, under the Program Investigo (INVESTIGO 2022, AGAUR- ref. BDNS 608313, file 2022 INV-1 00046 - Code 100046TC19). LR is supported by the IMI2 JU project IDEA-FAST (grant agreement 853981). LR is supported by the NIHR Newcastle Biomedical Research Centre based at The Newcastle upon Tyne Hospital National Health Service (NHS) Foundation Trust, Newcastle University, and the Cumbria, Northumberland, and Tyne and Wear NHS Foundation Trust and the NIHR/Wellcome Trust Clinical Research Facility infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. LR received funding from the NIHR Senior Investigator Awards (2020-2024 and 2024-2028). Content in this publication reflects the authors¿ views and neither IMI nor the European Union, EFPIA, NHS, NIHR or the Department of Health and Social Care are responsible for any use that may be made of the information contained herein.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Connecting real-world digital mobility assessment to clinical outcomes for regulatory and clinical endorsement-the Mobilise-D study protocol

  • Mikolaizak, A. Stefanie
  • García Aymerich, Judith
  • Bosch de Basea i Gómez, Magda, 1982-
  • Gimeno, Elena
  • Mobilise-D consortium
Background: The development of optimal strategies to treat impaired mobility related to ageing and chronic disease requires better ways to detect and measure it. Digital health technology, including body worn sensors, has the potential to directly and accurately capture real-world mobility. Mobilise-D consists of 34 partners from 13 countries who are working together to jointly develop and implement a digital mobility assessment solution to demonstrate that real-world digital mobility outcomes have the potential to provide a better, safer, and quicker way to assess, monitor, and predict the efficacy of new interventions on impaired mobility. The overarching objective of the study is to establish the clinical validity of digital outcomes in patient populations impacted by mobility challenges, and to support engagement with regulatory and health technology agencies towards acceptance of digital mobility assessment in regulatory and health technology assessment decisions. Methods/design: The Mobilise-D clinical validation study is a longitudinal observational cohort study that will recruit 2400 participants from four clinical cohorts. The populations of the Innovative Medicine Initiative-Joint Undertaking represent neurodegenerative conditions (Parkinson's Disease), respiratory disease (Chronic Obstructive Pulmonary Disease), neuro-inflammatory disorder (Multiple Sclerosis), fall-related injuries, osteoporosis, sarcopenia, and frailty (Proximal Femoral Fracture). In total, 17 clinical sites in ten countries will recruit participants who will be evaluated every six months over a period of two years. A wide range of core and cohort specific outcome measures will be collected, spanning patient-reported, observer-reported, and clinician-reported outcomes as well as performance-based outcomes (physical measures and cognitive/mental measures). Daily-living mobility and physical capacity will be assessed directly using a wearable device. These four clinical cohorts were chosen to obtain generalizable clinical findings, including diverse clinical, cultural, geographical, and age representation. The disease cohorts include a broad and heterogeneous range of subject characteristics with varying chronic care needs, and represent different trajectories of mobility disability. Discussion: The results of Mobilise-D will provide longitudinal data on the use of digital mobility outcomes to identify, stratify, and monitor disability. This will support the development of widespread, cost-effective access to optimal clinical mobility management through personalised healthcare. Further, Mobilise-D will provide evidence-based, direct measures which can be endorsed by regulatory agencies and health technology assessment bodies to quantify the impact of disease-modifying interventions on mobility. Trial registration: ISRCTN12051706., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The funding bodies do not have ultimate authority over any activities (study design, collection, management, analysis, interpretation of data, writing of reports and decision to submit for publication. A draft protocol for the clinical validation was provided as part of the grant/funding application. Content in this publication reflects the authors’ view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein. ISGlobal acknowledges support from the Spanish Ministry of Science, Innovation and Universities through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. Heleen Demeyer is a post-doctoral fellow of the FWO Flanders. Heiko Gaßner is supported by the Fraunhofer Internal Programs under Grant No. Attract 044-602140 and 044-602150
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Walking-related digital mobility outcomes as clinical trial endpoint measures: protocol for a scoping review

  • Polhemus, Ashley Marie
  • Bosch de Basea i Gómez, Magda, 1982-
  • Delgado-Ortiz, Laura
  • García Aymerich, Judith
  • Koch, Sarah
  • Frei, Anja
Introduction: Advances in wearable sensor technology now enable frequent, objective monitoring of real-world walking. Walking-related digital mobility outcomes (DMOs), such as real-world walking speed, have the potential to be more sensitive to mobility changes than traditional clinical assessments. However, it is not yet clear which DMOs are most suitable for formal validation. In this review, we will explore the evidence on discriminant ability, construct validity, prognostic value and responsiveness of walking-related DMOs in four disease areas: Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary disease and proximal femoral fracture. Methods and analysis: Arksey and O'Malley's methodological framework for scoping reviews will guide study conduct. We will search seven databases (Medline, CINAHL, Scopus, Web of Science, EMBASE, IEEE Digital Library and Cochrane Library) and grey literature for studies which (1) measure differences in DMOs between healthy and pathological walking, (2) assess relationships between DMOs and traditional clinical measures, (3) assess the prognostic value of DMOs and (4) use DMOs as endpoints in interventional clinical trials. Two reviewers will screen each abstract and full-text manuscript according to predefined eligibility criteria. We will then chart extracted data, map the literature, perform a narrative synthesis and identify gaps. Ethics and dissemination: As this review is limited to publicly available materials, it does not require ethical approval. This work is part of Mobilise-D, an Innovative Medicines Initiative Joint Undertaking which aims to deliver, validate and obtain regulatory approval for DMOs. Results will be shared with the scientific community and general public in cooperation with the Mobilise-D communication team. Registration: Study materials and updates will be made available through the Center for Open Science's OSFRegistry (https://osf.io/k7395)., The MOBILISE-D project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 820 820. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). HD is a postdoctoral research fellow of the FWO-Flanders. JGA, MBdB, LDO and SK acknowledge support from the Spanish Ministry of Science, Innovation and Universities through the 'Centro de Excelencia Severo Ochoa 2019–2023' Programme (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Programme.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Walking into aging: real-world mobility patterns and digital benchmarks from the InCHIANTI Study

  • Albites-Sanabria, Jose
  • Palumbo, Pierpaolo
  • Bandinelli, Stefania
  • D&apos;Ascanio, Ilaria
  • Mellone, Sabato
  • Paraschiv-Ionescu, Anisoara
  • Küderle, Arne
  • Cereatti, Andrea
  • Del Din, Silvia
  • Kluge, Felix
  • Gazit, Eran
  • Jansen, Carl-Philipp
  • Delgado-Ortiz, Laura
  • García Aymerich, Judith
  • Rochester, Lynn
  • Klenk, Jochen
  • Ferrucci, Luigi
  • Becker, Clemens
  • Chiari, Lorenzo
  • Palmerini, Luca
Mobility is a cornerstone of health and quality of life, particularly in older adults. Digital mobility outcomes (DMOs) from real-world walking data offer crucial insights into the functional status and early markers of mobility decline. This study provides reference values for walking activity, pace, rhythm, and gait bout-to-bout variability in community-dwelling older adults and evaluates the effects of age, sex, height, and weight on these parameters. Using data from 200 older adults (aged 65-94 years) from the InCHIANTI Study and applying the Mobilise-D computational pipeline, we analyzed real-world walking over a week. Significant differences by sex and age were found, with males showing higher walking activity in younger age groups (65-74 and 75-84 years) but not in the oldest group (85-94 years). Additionally, we observed non-linear trends in mobility metrics with age, indicating an accelerated reduction in mobility at certain age ranges. These findings underscore the importance of monitoring real-world walking data to pinpoint critical periods of mobility decline and guide targeted interventions. This work offers valuable benchmarks for clinical assessments and future research., We want to acknowledge the participants who volunteered to take part in the clinical studies. Their contribution has been vital to the successful completion of the present study. The InCHIANTI baseline study (1998–2000) was supported as a “targeted project” (ICS110.1/RF97.71) by the Italian Ministry of Health and in part by the U.S. National Institute on Aging (Contracts: 263 MD 9164 and 263 MD 821336); the InCHIANTI follow-up study 1 (2001–2003) was funded by the U.S. National Institute on Aging (Contracts: N.1-AG[1]1-1 and N.1-AG-1-2111); the InCHIANTI follow-up study 4 and 5 were supported by the Agency for Regional Health Care of Tuscany (Reg. n° 586/R, 26/10/2012). This research was co-funded by the Italian Complementary National Plan PNC-I.1 Research initiatives for innovative technologies and pathways in the health and welfare sector” D.D. 931 of 06/06/2022, DARE - DigitAl lifelong pRevEntion initiative, code PNC0000002, CUP: B53C22006450001. The study has been funded in part by the European Union (Seventh Framework Program (FP7/2007-2013) under grant agreement No.: 288940 (FARSEEING project)), and by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820820 (Mobilise[1]D). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. S.D.D. was also supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) project IDEA-FAST - Grant Agreement 853981 and by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear (CNTW) NHS Foundation Trust. S.D.D. was supported by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. S.D.D. was also supported by the UK Research and Innovation (UKRI) Engineering and Physical Sciences Research Council (EPSRC) (Grant Ref: EP/W031590/1, Grant Ref: EP/X031012/1 and Grant Ref: EP/X036146/1).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes

  • Polhemus, Ashley Marie
  • Delgado-Ortiz, Laura
  • Cardenas, Gabriela
  • Koch, Sarah
  • Bosch de Basea i Gómez, Magda, 1982-
  • García Aymerich, Judith
  • Mobilise-D
Physical mobility is essential to health, and patients often rate it as a high-priority clinical outcome. Digital mobility outcomes (DMOs), such as real-world gait speed or step count, show promise as clinical measures in many medical conditions. However, current research is nascent and fragmented by discipline. This scoping review maps existing evidence on the clinical utility of DMOs, identifying commonalities across traditional disciplinary divides. In November 2019, 11 databases were searched for records investigating the validity and responsiveness of 34 DMOs in four diverse medical conditions (Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary disease, hip fracture). Searches yielded 19,672 unique records. After screening, 855 records representing 775 studies were included and charted in systematic maps. Studies frequently investigated gait speed (70.4% of studies), step length (30.7%), cadence (21.4%), and daily step count (20.7%). They studied differences between healthy and pathological gait (36.4%), associations between DMOs and clinical measures (48.8%) or outcomes (4.3%), and responsiveness to interventions (26.8%). Gait speed, step length, cadence, step time and step count exhibited consistent evidence of validity and responsiveness in multiple conditions, although the evidence was inconsistent or lacking for other DMOs. If DMOs are to be adopted as mainstream tools, further work is needed to establish their predictive validity, responsiveness, and ecological validity. Cross-disciplinary efforts to align methodology and validate DMOs may facilitate their adoption into clinical practice., The Mobilise-D project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 820820. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This publication reflects the authors’ views and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein. H.D. is a postdoctoral research fellow of the FWO-Flanders. ISGlobal acknowledges support from the Spanish Ministry of Science, Innovation, and Universities through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Technical validation of real-world monitoring of gait: a multicentric observational study

  • Mazzà, Claudia
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Koch, Sarah
  • Rochester, Lynn
Introduction: Existing mobility endpoints based on functional performance, physical assessments and patient self-reporting are often affected by lack of sensitivity, limiting their utility in clinical practice. Wearable devices including inertial measurement units (IMUs) can overcome these limitations by quantifying digital mobility outcomes (DMOs) both during supervised structured assessments and in real-world conditions. The validity of IMU-based methods in the real-world, however, is still limited in patient populations. Rigorous validation procedures should cover the device metrological verification, the validation of the algorithms for the DMOs computation specifically for the population of interest and in daily life situations, and the users' perspective on the device. Methods and analysis: This protocol was designed to establish the technical validity and patient acceptability of the approach used to quantify digital mobility in the real world by Mobilise-D, a consortium funded by the European Union (EU) as part of the Innovative Medicine Initiative, aiming at fostering regulatory approval and clinical adoption of DMOs.After defining the procedures for the metrological verification of an IMU-based device, the experimental procedures for the validation of algorithms used to calculate the DMOs are presented. These include laboratory and real-world assessment in 120 participants from five groups: healthy older adults; chronic obstructive pulmonary disease, Parkinson's disease, multiple sclerosis, proximal femoral fracture and congestive heart failure. DMOs extracted from the monitoring device will be compared with those from different reference systems, chosen according to the contexts of observation. Questionnaires and interviews will evaluate the users' perspective on the deployed technology and relevance of the mobility assessment. Ethics and dissemination: The study has been granted ethics approval by the centre's committees (London-Bloomsbury Research Ethics committee; Helsinki Committee, Tel Aviv Sourasky Medical Centre; Medical Faculties of The University of Tübingen and of the University of Kiel). Data and algorithms will be made publicly available. Trial registration number: ISRCTN (12246987)., We acknowledge support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. SDD, AY and LRo are also supported by the Newcastle Biomedical Research Centre (BRC) based at Newcastle upon Tyne and Newcastle University. CM, BS, LVG and EB are also supported by the Sheffield Biomedical Research Centre (BRC) based at the Sheffield Teaching Hospital and the University of Sheffield. The work was also supported by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust and the CRF at the Sheffield Teaching Hospital. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care or the funders.This study was co-funded by the European Union’s Horizon 2020 research and innovation programme and EFPIA via the Innovative Medicine Initiative 2 (Mobilise-D project, grant number IMI22017-13-7-820820). The views expressed are those of the authors and not necessarily those of the IMI, the European Union, the EFPIA, or any Associated Partners. We acknowledge the support of Grünenthal GmbH via the funding of a PhD scholarship directly dedicated to the technical validation protocol.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The construct validity of real-world digital mobility outcomes in people with COPD

  • Megaritis, Dimitrios
  • de las Heras, Martí
  • Alcaraz-Serrano, Victoria
  • Alvarez, Paula
  • Buekers, Joren
  • Delgado-Ortiz, Laura
  • Gimeno Santos, Elena, 1980-
  • Josa-Culleré, Alícia
  • Koch, Sarah
  • Lemos, Jorge
  • García Aymerich, Judith
Background: Recent advances in wearable technologies make it possible to accurately quantify real-world mobility performance through technically validated digital mobility outcomes (DMOs). The aim of the present study was to evaluate the construct validity (convergent, divergent, and known-groups validity) of 24 DMOs quantifying walking activity (amount and pattern) and gait (pace, rhythm and bout-to-bout variability) in people with COPD. Methods: Part of the Mobilise-D observational cohort study, people with COPD, recruited from seven European sites, wore an activity monitor for 7 days during daily life. Functional capacity, health status, dyspnoea, lung function, quadriceps torque and experience of difficulty with physical activity were used as constructs for convergent validity testing (Pearson/Spearman correlation coefficients). Diastolic blood pressure was used as an unrelated construct for divergent validity (criterion: |r|<0.2). Known-groups validity was evaluated across Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages (I-IV), GOLD ABE and modified Medical Research Council dyspnoea grades (linear models with p-for-trend). Results: 549 participants (37% females), had mean±sd age of 68±8 years, post-bronchodilator forced expiratory volume in 1 s (FEV1) 54±20% predicted and 6-min walk distance 416±119 m. Convergent validity was supported for the majority of DMOs (17 out of 24) with correlation coefficients meeting or exceeding the a priori hypotheses by clinical experts. All DMOs supported divergent validity. 22 out of 24 DMOs distinguished between disease severity groups successfully. Expert consensus supported construct validity of 17 DMOs. Conclusions: Construct validity was supported for all walking activity (amount and pattern) DMOs, and most of the gait (pace, rhythm, and bout-to-bout variability) DMOs, indicating the clinical utility of these measures., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking (JU) under grant agreement number 820820. This JU receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Content in this publication reflects the authors' view and neither IMI nor the European Union, EFPIA or any associated partners are responsible for any use that may be made of the information contained herein. Funding information for this article has been deposited with the Open Funder Registry.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Digital assessment of real-world walking in people with impaired mobility: How many hours and days are needed?

  • Buekers, Joren
  • Koch, Sarah
  • Marchena, José
  • Lemos, Jorge
  • García Aymerich, Judith
Background: Impaired mobility increases falls and mortality risk. However, guidelines to reliably assess real-world walking activity and gait remain undefined. We aimed to (i) determine the minimum daily wear time during waking hours (7:00–22:00) for a valid measurement day, (ii) identify the minimum number of valid days, and (iii) weekend days, to reliably assess weekly walking activity and gait parameters, and (iv) provide recommendations for reliable real-world walking assessments. Methods: Participants with chronic obstructive pulmonary disease (n = 565), multiple sclerosis (n = 558), Parkinson’s disease (n = 543) or proximal femoral fracture (n = 487) from 10 countries were asked to wear a single wearable device on the lower back, 24 h/day for seven days, resulting in 13,191 measurement days. The Mobilise-D processing pipeline was used to obtain 24 daily walking activity and gait parameters. Minimum daily wear time was determined as the highest wear time category that did not statistically change parameter values. Intraclass correlation coefficients ≥ 0.80 determined the minimum number of valid measurement and weekend days. Results: The minimum daily wear time varied between “no requirement” (13% of parameter-condition combinations) and > 14 h (19%), with higher requirements for walking activity than gait parameters. The minimum number of days ranged from 1 (17%) to > 7 days (6%), and was higher for parameters that are yet to be clinically validated. There was no evidence of a weekend nor health condition effect on parameter reliability. Conclusions: For studies involving multiple walking activity and gait parameters or health conditions, expert consensus recommends a minimum of > 12 h of daily wear time across ≥ 3 days. For studies that involve specific parameters or health conditions, individual recommendations are provided within the manuscript. Supplementary Information: The online version contains supplementary material available at 10.1186/s12966-025-01851-3., This work was supported by the Mobilise-D project that received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The Barcelona Institute for Global Health (ISGlobal) receives support from the grant CEX2023-0001290-S funded by MCIN/AEI/https://doi.org/10.13039/5011 00011033, and support from the Generalitat de Catalunya through the CERCA rogram. Joren Buekers (FJC2021-046458-I) and Sarah Koch (IJC2020-044363-I) received funding from the Juan de la Cierva Formación and Incorporación, respectively, financed by MICIU/AEI/https://doi.org/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR. This paper presents independent research supported by the National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre (BRC), and the NIHR Sheffield BRC. The NIHR Newcastle BRC is a partnership between Newcastle Hospitals NHS Foundation Trust, Newcastle University, and Cumbria, Northumberland and Tyne and Wear NHS Foundation Trust and is funded by the NIHR. The research was also supported by the NIHR Sheffield Biomedical Research Centre based at the Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield and carried out at the NIHR Sheffield Clinical Research Facility at the Sheffield Teaching Hospitals NHS Foundation Trust. LR, AY and SDD were also supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) project IDEA-FAST - Grant Agreement 853981. LR, AY and SDD were supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear (CNTW) NHS Foundation Trust and, the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. SDD was supported by the UK Research and Innovation (UKRI) Engineering and Physical Sciences Research Council (EPSRC) (Grant Ref: EP/W031590/1, Grant Ref: EP/X031012/1 and Grant Ref: EP/X036146/1). AY is also supported by the Michael J Fox Foundation (grant references MJFF-022735 & MJFF-022737), UK Engineering and Physical Sciences Research Council (EPSRC), grant number EP/X036146/1, Intercept Pharmaceuticals, NIHR HTA (grant reference NIHR129175). She is in receipt of grants from Parkinson's UK, Weston Brain Institute, Dunhill Medical Trust and Cure Parkinson's Trust. HD is a post-doctoral researcher of FWO Flanders (12ZW822N). The views expressed are those of the authors and not necessarily those of the IMI, the European Union, the EFPIA, NHS, NIHR, the Department of Health and Social Care or any Associated Partners
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device

  • Kirk, Cameron
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Koch, Sarah
  • Mobilise-D consortium
This study aimed to validate a wearable device's walking speed estimation pipeline, considering complexity, speed, and walking bout duration. The goal was to provide recommendations on the use of wearable devices for real-world mobility analysis. Participants with Parkinson's Disease, Multiple Sclerosis, Proximal Femoral Fracture, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure, and healthy older adults (n = 97) were monitored in the laboratory and the real-world (2.5 h), using a lower back wearable device. Two walking speed estimation pipelines were validated across 4408/1298 (2.5 h/laboratory) detected walking bouts, compared to 4620/1365 bouts detected by a multi-sensor reference system. In the laboratory, the mean absolute error (MAE) and mean relative error (MRE) for walking speed estimation ranged from 0.06 to 0.12 m/s and - 2.1 to 14.4%, with ICCs (Intraclass correlation coefficients) between good (0.79) and excellent (0.91). Real-world MAE ranged from 0.09 to 0.13, MARE from 1.3 to 22.7%, with ICCs indicating moderate (0.57) to good (0.88) agreement. Lower errors were observed for cohorts without major gait impairments, less complex tasks, and longer walking bouts. The analytical pipelines demonstrated moderate to good accuracy in estimating walking speed. Accuracy depended on confounding factors, emphasizing the need for robust technical validation before clinical application.Trial registration: ISRCTN - 12246987., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). SDD, LR, AY were also supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) project IDEA-FAST—Grant Agreement 853981. LA, LR, AY and SDD were also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear (CNTW) NHS Foundation Trust. LA, LR, AY and SDD were also supported by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. This study was also supported by the National Institute for Health Research (NIHR) through the Sheffield Biomedical Research Centre (BRC, Grant Number IS-BRC-1215–20017). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), and from the Generalitat de Catalunya through the CERCA Program. All opinions are those of the authors and not the funders. The content in this publication reflects the authors’ view, and neither IMI nor the European Union, EFPIA, NHS, NIHR, DHSC, or any associated partners are responsible for any use that may be made of the information contained herein.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Investigating the prognostic value of digital mobility outcomes in patients with chronic obstructive pulmonary disease: a systematic literature review and meta-analysis

  • Buttery, Sara C.
  • Buekers, Joren
  • Delgado-Ortiz, Laura
  • García Aymerich, Judith
  • Gimeno Santos, Elena, 1980-
  • Koch, Sarah
  • Hopkinson, Nicholas S.
Background: Reduced mobility is a central feature of COPD. Assessment of mobility outcomes that can be measured digitally (digital mobility outcomes (DMOs)) in daily life such as gait speed and steps per day is increasingly possible using devices such as pedometers and accelerometers, but the predictive value of these measures remains unclear in relation to key outcomes such as hospital admission and survival. Methods: We conducted a systematic review, nested within a larger scoping review by the MOBILISE-D consortium, addressing DMOs in a range of chronic conditions. Qualitative and quantitative analysis considering steps per day and gait speed and their association with clinical outcomes in COPD patients was performed. Results: 21 studies (6076 participants) were included. Nine studies evaluated steps per day and 11 evaluated a measure reflecting gait speed in daily life. Negative associations were demonstrated between mortality risk and steps per day (per 1000 steps) (hazard ratio (HR) 0.81, 95% CI 0.75-0.88, p<0.001), gait speed (<0.80 m·s-1) (HR 3.55, 95% CI 1.72-7.36, p<0.001) and gait speed (per 1.0 m·s-1) (HR 7.55, 95% CI 1.11-51.3, p=0.04). Fewer steps per day (per 1000) and slow gait speed (<0.80 m·s-1) were also associated with increased healthcare utilisation (HR 0.80, 95% CI 0.72-0.88, p<0.001; OR 3.36, 95% CI 1.42-7.94, p=0.01, respectively). Available evidence was of low-moderate quality with few studies eligible for meta-analysis. Conclusion: Daily step count and gait speed are negatively associated with mortality risk and other important outcomes in people with COPD and therefore may have value as prognostic indicators in clinical trials, but the quantity and quality of evidence is limited. Larger studies with consistent methodologies are called for., This work was supported by the Mobilise-D project; the Mobilise-D project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 820820. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This publication reflects the authors’ views and neither IMI nor the European Union, EFPIA or any Associated Partners are responsible for any use that may be made of the information contained herein. H. Demeyer is a postdoctoral research fellow of the FWO-Flanders. ISGlobal acknowledges support from the grant CEX2018–000806-S funded by MCIN/AEI/ 10.13039/501100011033, and the Generalitat de Catalunya through the CERCA Program and L. Delgado-Ortiz is funded by the following grant: Contratos Predoctorales de Formación en Investigación en Salud (PFIS) 2021 of the AES with Exp. FI21/00113 from ISCIII, and the European Social Fund Plus (ESF+). This research was supported by the NIHR Imperial Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care, the IMI, the European Union, the EFPIA or any Associated Partners. Funding information for this article has been deposited with the Crossref Funder Registry.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Evaluating the accuracy and reliability of real-world digital mobility outcomes in older adults after hip fracture: Cross-sectional observational study

  • Berge, Martin A.
  • García Aymerich, Judith
  • Koch, Sarah
  • Vereijken, Beatrix
Background: Algorithms estimating real-world digital mobility outcomes (DMOs) are increasingly validated in healthy adults and various disease cohorts. However, their accuracy and reliability in older adults after hip fracture, who often walk slowly for short durations, is underexplored. Objective: This study examined DMO accuracy and reliability in a hip fracture cohort considering walking bout (WB) duration, physical function, days since surgery, and walking aid use. Methods: In total, 19 community-dwelling participants were real-world monitored for 2.5 hours using a lower back wearable device and a reference system combining inertial modules, distance sensors, and pressure insoles. A total of 6 DMO estimates from 164 WBs from 58% (11/19) of the participants (aged 71-90 years; assessed 32-390 days after surgery; Short Physical Performance Battery [SPPB] scores of 3-12; gait speed range 0.39-1.34 m/s) were assessed against the reference system at the WB and participant level. We stratified by WB duration (all WBs, WBs of >10 seconds, WBs of 10-30 seconds, and WBs of >30 seconds) and lower versus higher SPPB scores and observed whether days since surgery and walking aid use affected DMO accuracy and reliability. Results: Across WBs, walking speed and distance ranged from 0.25 to 1.29 m/s and from 1.7 to 436.5 m, respectively. Estimation of walking speed, cadence, stride duration, number of steps, and distance stratified by WB duration showed intraclass correlation coefficients (ICCs) ranging from 0.50 to 0.99 and mean relative errors (MREs) from -6.9% to 12.8%. Stride length estimation showed poor reliability, with ICCs ranging from 0.30 to 0.49 and MREs from 6.1% to 13.2%. Walking speed and distance ICCs in the higher-SPPB score group ranged from 0.85 to 0.99, and MREs ranged from -10.1% to -1.7%. In the lower-SPPB score group, walking speed and distance ICCs ranged from 0.17 to 0.99, and MREs ranged from 13.5% to 32.6%. There was no discernible effect of time since surgery or walking aid use. Conclusions: In total, 5 accurate and reliable real-world DMOs were identified in older adults after hip fracture: walking speed, cadence, stride duration, number of steps, and distance. Accuracy and reliability of most DMOs improved when excluding WBs of <10 seconds and were higher for WBs of >30 seconds than for WBs of 10 to 30 seconds and for participants with higher physical function. DMOs capture daily gait as early as 1 month after surgery also in people using walking aids. However, as most WBs in this cohort were short, there was a trade-off between improving accuracy and reliability by excluding short WBs and losing a substantial amount of data. These results have important implications for establishing the clinical validity of DMOs and evaluating the effects of interventions on daily-life gait, thereby facilitating the design of optimal care pathways., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking under grant 820820. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations. The authors thank the Mobilise-D technical validation study team of work package 2, all participants who devoted their time and energy to this taxing protocol in times of COVID-19, and Miriam Dinger at the Robert Bosch Foundation for Medical Research and Dr Tim Klüter at University Hospital Schleswig-Holstein for their indispensable help in recruiting patients. MAB acknowledges ChatGPT, an artificial intelligence model by OpenAI, for suggestions that helped improve the clarity of some sentences in this paper. SDD and LR were also supported by the Identifying Digital Endpoints to Assess Fatigue, Sleep, and Activities in Daily Living in Neurodegenerative Disorders and Immune-Mediated Inflammatory Diseases project that has received funding from the IMI 2 Joint Undertaking under grant agreement 853981. LR is a National Institute for Health and Care Research (NIHR) senior investigator. Both SDD and LR were supported by the NIHR Newcastle Biomedical Research Centre based at the Newcastle upon Tyne Hospitals National Health Service (NHS) Foundation Trust; Newcastle University; and the Cumbria, Northumberland, Tyne, and Wear NHS Foundation Trust. SDD and LR were also supported by the NIHR and Wellcome Trust Clinical Research Facility infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. SDD was supported by the UK Research and Innovation Engineering and Physical Sciences Research Council (grant reference EP/X031012/1 and EP/X036146/1). The Barcelona Institute for Global Health acknowledges support from grant CEX2018-000806-S funded by the Ministry of Science, Innovation, and Universities and the State Research Agency (MCIN/AEI/10.13039/501100011033) and support from the Government of Catalonia through the Research Centers of Catalonia program. The views expressed in this publication are those of the authors and do not necessarily reflect those of the IMI, the European Union, the European Federation of Pharmaceutical Industries and Associations, any associated partners, the NIHR, or the Department of Health and Social Care, who are not responsible for any use that may be made of the information contained herein.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Gait differences between COPD and healthy controls: systematic review and meta-analysis

  • Buekers, Joren
  • Delgado-Ortiz, Laura
  • Megaritis, Dimitrios
  • Polhemus, Ashley Marie
  • Breuls, Sofie
  • Buttery, Sara C.
  • Chynkiamis, Nikolaos
  • Demeyer, Heleen
  • Gimeno Santos, Elena, 1980-
  • Hume, Emily
  • Koch, Sarah
  • Williams, Parris
  • Wuyts, Marieke
  • Hopkinson, Nicholas S.
  • Vogiatzis, Ioannis
  • Troosters, Thierry
  • Frei, Anja
  • García Aymerich, Judith
Background: Despite the importance of gait as a determinant of falls, disability and mortality in older people, understanding of gait impairment in COPD is limited. This study aimed to identify differences in gait characteristics during supervised walking tests between people with COPD and healthy controls. Methods: We searched 11 electronic databases, supplemented by Google Scholar searches and manual collation of references, in November 2019 and updated the search in July 2021. Record screening and information extraction were performed independently by one reviewer and checked for accuracy by a second. Meta-analyses were performed in studies not considered at a high risk of bias. Results: Searches yielded 21 085 unique records, of which 25 were included in the systematic review (including 1015 people with COPD and 2229 healthy controls). Gait speed was assessed in 17 studies (usual speed: 12; fast speed: three; both speeds: two), step length in nine, step duration in seven, cadence in six, and step width in five. Five studies were considered at a high risk of bias. Low-quality evidence indicated that people with COPD walk more slowly than healthy controls at their usual speed (mean difference (MD) -19 cm·s-1, 95% CI -28 to -11 cm·s-1) and at a fast speed (MD -30 cm·s-1, 95% CI -47 to -13 cm·s-1). Alterations in other gait characteristics were not statistically significant. Conclusion: Low-quality evidence shows that people with COPD walk more slowly than healthy controls, which could contribute to an increased falls risk. The evidence for alterations in spatial and temporal components of gait was inconclusive. Gait impairment appears to be an important but understudied area in COPD., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement number 820820. This JU receives support from the European Union's Horizon 2020 research and innovation programme, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The Barcelona Institute for Global Health (ISGlobal) receives support from the Spanish Ministry of Science, Innovation and Universities through the “Centro de Excelencia Severo Ochoa 2019–2023” programme (CEX 2018-000806-S), and support from the Generalitat de Catalunya through the CERCA programme. The views expressed are those of the authors and not necessarily those of the IMI, the European Union, the EFPIA or any associated partners. L. Delgado-Ortiz receives funding from the grant “Contratos Predoctorales de Formación en Investigación en Salud (PFIS) 2021 of the AES with Exp. FI21/00113” from ISCIII, and the European Social Fund Plus (ESF+). Funding information for this article has been deposited with the Crossref Funder Registry.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Association of cut-point free metrics and common clinical tests among older adults after proximal femoral fracture

  • Younesian, Hananeh
  • Singleton, David
  • Vereijken, Beatrix
  • García Aymerich, Judith
  • Rochester, Lynn
  • Aursand Berge, Martin
  • Engdal, Monika
  • Buekers, Joren
  • Koch, Sarah
  • Helbostad, Jorunn L.
  • Alvarez, Paula
  • Jansen, Carl-Philipp
  • Aminian, Kamiar
  • Paraschiv-Ionescu, Anisoara
  • Becker, Clemens
  • Caulfield, Brian
  • Mobilise-D consortium
Wearable and lightweight devices facilitate real-world physical activity (PA) assessments. MX metrics, as a cut-point-free parameter, evaluate acceleration above which the most active X minutes are accumulated. It provides insights into the intensity of PA over specific durations. This study evaluated the association of MX metrics and clinical tests in older adults recovering from proximal femoral fracture (PFF). Analyses were conducted on the PFF cohort from the baseline assessment of the Mobilise-D project using an accelerometer-based device. Participants (N = 396) were categorized into four recovery groups: acute, post-acute, extended recovery, and long-term recovery. Mobility capacity was assessed through the 6 min walking test (6MinWT), Short Physical Performance Battery (SPPB), 4-m walking test (4MWT), and hand grip (HG) strength. Mobility perception was evaluated using the Late-Life Function and Disability Instrument (LLFDI). Eight MX metrics (M1-M90) were calculated using the GGIR package in R. Results showed a moderate to strong positive correlation between M1 and M30 and lower limb mobility capacity tests and mobility perception (Lower Extremity domains) particularly in the extended and long-term recovery groups. MX metrics can be used for measuring PA intensity among older adults recovering from PFF. Hence, MX metrics have a high potential for clinical use as personalized PA targets in PFF rehabilitation., H.Y. has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 101034252. This research is supported by Taighde Éireann—Research Ireland. The Mobilise-D consortium received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820820. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Laboratory and free-living gait performance in adults with COPD and healthy controls

  • Buekers, Joren
  • Koch, Sarah
  • García Aymerich, Judith
Background: Gait characteristics are important risk factors for falls, hospitalisations and mortality in older adults, but the impact of COPD on gait performance remains unclear. We aimed to identify differences in gait characteristics between adults with COPD and healthy age-matched controls during 1) laboratory tests that included complex movements and obstacles, 2) simulated daily-life activities (supervised) and 3) free-living daily-life activities (unsupervised). Methods: This case-control study used a multi-sensor wearable system (INDIP) to obtain seven gait characteristics for each walking bout performed by adults with mild-to-severe COPD (n=17; forced expiratory volume in 1 s 57±19% predicted) and controls (n=20) during laboratory tests, and during simulated and free-living daily-life activities. Gait characteristics were compared between adults with COPD and healthy controls for all walking bouts combined, and for shorter (≤30 s) and longer (>30 s) walking bouts separately. Results: Slower walking speed (-11 cm·s-1, 95% CI: -20 to -3) and lower cadence (-6.6 steps·min-1, 95% CI: -12.3 to -0.9) were recorded in adults with COPD compared to healthy controls during longer (>30 s) free-living walking bouts, but not during shorter (≤30 s) walking bouts in either laboratory or free-living settings. Double support duration and gait variability measures were generally comparable between the two groups. Conclusion: Gait impairment of adults with mild-to-severe COPD mainly manifests during relatively long walking bouts (>30 s) in free-living conditions. Future research should determine the underlying mechanism(s) of this impairment to facilitate the development of interventions that can improve free-living gait performance in adults with COPD., Support statement: This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement number 820820. This JU receives support from the European Union's Horizon 2020 research and innovation programme, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). S. Del Din and L. Rochester were also supported by the Innovative Medicines Initiative 2 (IMI2) JU project IDEA-FAST – grant agreement 853981. S. Del Din, L. Alcock and L. Rochester were also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear NHS Foundation Trust, and by the NIHR/Welcome Trust Clinical Research Facility infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. C. Mazzà and E. Buckley were also supported by the Sheffield BRC based at the Sheffield Teaching Hospital and the University of Sheffield. H. Demeyer is a post-doctoral research fellow of the Flemish Research Foundation (FWO Flanders). The Barcelona Institute for Global Health (ISGlobal) receives support from the Spanish Ministry of Science, Innovation and Universities through the “Centro de Excelencia Severo Ochoa 2019–2023” Programme (CEX 2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Programme. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health, the IMI, the European Union, the EFPIA or any Associated Partners. Funding information for this article has been deposited with the Crossref Funder Registry.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Aging towards walkable futures: insights from a multidisciplinary workshop held in Barcelona, Spain

  • Vall Garcia, Enric
  • Delgado-Ortiz, Laura
  • Alcock, Lisa
  • Coll Planas, Laura
  • Garcia-Navarro, Jose Augusto
  • Iwarsson, Susanne
  • Jansà, Josep Maria
  • Jansen, Carl-Philipp
  • Koch, Sarah
  • Schwartz, Simon
  • Rantakokko, Merja
  • Sarukhan, Adelaida
  • van Staalduinen, Willeke
  • Rochester, Lynn
  • García Aymerich, Judith
Background: The aging of the world's population and the increase in sedentary lifestyles are leading to an increase in walking impairments at older ages. Here, we aimed to comprehensively discuss walking in the context of an aging population; and identify and agree on a list of future research priorities and policy actions. Methods: We followed a participatory approach and held a multidisciplinary two-day workshop on October, 2023 in Barcelona, Spain, with experts in the fields of aging and walking, and participants from the general public. Results: A total of 56 national and international participants, from a multidisciplinary background, joined the workshop. They had a median age of 40 years (range 24-83), and 62% were female. Participants discussed the meaning of walking from different perspectives and its change with age and in the presence of diverse mobility-impairing conditions; the emotional and social components of walking; and the role of the environment in walking. Participants identified unmet needs, research priorities and policy actions related to walking in older ages. Conclusions: This two-day workshop provided a space for professionals and public to comprehensively discuss walking at older ages. Participants highlighted the relevance of a better and more comprehensive assessment of walking; the need to shift focus towards comprehensive health that considers physical, emotional and social aspects as well as individuals' preferences and expectations; and the importance of translating research into action. Future work can draw on the discussions held during this event in a thought-provoking and hypothesis-generating way., ISGlobal acknowledges support from the grant CEX2018-000806-S funded by MCIN/AEI/https://doi.org/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Programme. This work was also supported by the Severo-Ochoa program at ISGlobal and the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The content of the current publication reflects the authors’ view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein. LD-O receives funding from the grant “Contratos Predoctorales de Formación en Investigación en Salud (PFIS) 2021 of the AES with Exp. FI21/00113” from ISCIII, and the European Social Fund Plus (ESF+). LR acknowledges infrastructure support provided by Newcastle Biomedical Research Centre (BRC) hosted by Newcastle upon Tyne Hospitals National Health Service (NHS) Foundation Trust and Newcastle University, UK.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Listening to the patients’ voice: a conceptual framework of the walking experience

  • Delgado-Ortiz, Laura
  • Polhemus, Ashley Marie
  • Keogh, Alison
  • Sutton, Norman
  • Remmele, Werner
  • Hansen, Clint
  • Kluge, Felix
  • Sharrack, Basil
  • Becker, Clemens
  • Troosters, Thierry
  • Maetzler, Walter
  • Rochester, Lynn
  • Frei, Anja
  • Puhan, Milo A.
  • García Aymerich, Judith
Includes supplementary materials for the online appendix., Walking is crucial for an active and healthy ageing, but the perspectives of individuals living with walking impairment are still poorly understood. To identify and synthesise evidence describing walking as experienced by adults living with mobility-impairing health conditions and to propose an empirical conceptual framework of walking experience. We performed a systematic review and meta-ethnography of qualitative evidence, searching seven electronic databases for records that explored personal experiences of walking in individuals living with conditions of diverse aetiology. Conditions included Parkinson’s disease, multiple sclerosis, chronic obstructive pulmonary disease, hip fracture, heart failure, frailty and sarcopenia. Data were extracted, critically appraised using the NICE quality checklist and synthesised using standardised best practices.From 2,552 unique records, 117 were eligible. Walking experience was similar across conditions and described by seven themes: (i) becoming aware of the personal walking experience, (ii) the walking experience as a link between individuals’ activities and sense of self, (iii) the physical walking experience, (iv) the mental and emotional walking experience, (v) the social walking experience, (vi) the context of the walking experience and (vii) behavioural and attitudinal adaptations resulting from the walking experience. We propose a novel conceptual framework that visually represents the walking experience, informed by the interplay between these themes. A multi-faceted and dynamic experience of walking was common across health conditions. Our conceptual framework of the walking experience provides a novel theoretical structure for patient-centred clinical practice, research and public health., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Content in this publication reflects the authors’ view and neither IMI nor the European Union, EFPIA or any associated partners are responsible for any use that may be made of the information contained herein. ISGlobal acknowledges support from the Spanish Ministry of Science, Innovation, and Universities through the ‘Centro de Excelencia Severo Ochoa 2019–2023’ Programme (CEX2018-000806-S) and support from the Generalitat de Catalunya through the CERCA Programme.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Ecological validity of a deep learning algorithm to detect gait events from real-life walking bouts in mobility-limiting diseases

  • Romijnders, Robbin
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Koch, Sarah
  • Maetzler, Walter
Introduction: The clinical assessment of mobility, and walking specifically, is still mainly based on functional tests that lack ecological validity. Thanks to inertial measurement units (IMUs), gait analysis is shifting to unsupervised monitoring in naturalistic and unconstrained settings. However, the extraction of clinically relevant gait parameters from IMU data often depends on heuristics-based algorithms that rely on empirically determined thresholds. These were mainly validated on small cohorts in supervised settings. Methods: Here, a deep learning (DL) algorithm was developed and validated for gait event detection in a heterogeneous population of different mobility-limiting disease cohorts and a cohort of healthy adults. Participants wore pressure insoles and IMUs on both feet for 2.5 h in their habitual environment. The raw accelerometer and gyroscope data from both feet were used as input to a deep convolutional neural network, while reference timings for gait events were based on the combined IMU and pressure insoles data. Results and discussion: The results showed a high-detection performance for initial contacts (ICs) (recall: 98%, precision: 96%) and final contacts (FCs) (recall: 99%, precision: 94%) and a maximum median time error of -0.02 s for ICs and 0.03 s for FCs. Subsequently derived temporal gait parameters were in good agreement with a pressure insoles-based reference with a maximum mean difference of 0.07, -0.07, and <0.01 s for stance, swing, and stride time, respectively. Thus, the DL algorithm is considered successful in detecting gait events in ecologically valid environments across different mobility-limiting diseases., This study was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). LA, LR, AY, and SD were also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at Newcastle upon Tyne Hospital NHS Foundation Trust and Newcastle University and the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon the Tyne Hospitals NHS Foundation Trust. This study was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) through the project B9 of the Collaborative Research Centre CRC 1261 Magnetoelectric Sensors: From Composite Materials to Biomagnetic Diagnostics.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A Roadmap to inform development, validation and approval of digital mobility outcomes: The Mobilise-D approach

  • Rochester, Lynn
  • Mazzà, Claudia
  • Mueller, Arne
  • Caulfield, Brian
  • McCarthy, Marie
  • Becker, Clemens
  • Miller, Ram
  • Piraino, Paolo
  • Viceconti, Marco
  • Dartee, Wilhelmus
  • García Aymerich, Judith
  • Aydemir, Aida A.
  • Vereijken, Beatrix
  • Arnera, Valdo
  • Ammour, Nadir
  • Jackson, Michael
  • Hache, Tilo
  • Roubenoff, Ronenn
Health care has had to adapt rapidly to COVID-19, and this in turn has highlighted a pressing need for tools to facilitate remote visits and monitoring. Digital health technology, including body-worn devices, offers a solution using digital outcomes to measure and monitor disease status and provide outcomes meaningful to both patients and health care professionals. Remote monitoring of physical mobility is a prime example, because mobility is among the most advanced modalities that can be assessed digitally and remotely. Loss of mobility is also an important feature of many health conditions, providing a read-out of health as well as a target for intervention. Real-world, continuous digital measures of mobility (digital mobility outcomes or DMOs) provide an opportunity for novel insights into health care conditions complementing existing mobility measures. Accepted and approved DMOs are not yet widely available. The need for large collaborative efforts to tackle the critical steps to adoption is widely recognised. Mobilise-D is an example. It is a multidisciplinary consortium of 34 institutions from academia and industry funded through the European Innovative Medicines Initiative 2 Joint Undertaking. Members of Mobilise-D are collaborating to address the critical steps for DMOs to be adopted in clinical trials and ultimately health care. To achieve this, the consortium has developed a roadmap to inform the development, validation and approval of DMOs in Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary disease and recovery from proximal femoral fracture. Here we aim to describe the proposed approach and provide a high-level view of the ongoing and planned work of the Mobilise-D consortium. Ultimately, Mobilise-D aims to stimulate widespread adoption of DMOs through the provision of device agnostic software, standards and robust validation in order to bring digital outcomes from concept to use in clinical trials and health care., The MOBILISE-D project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 820820. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Design and validation of a multi-task, multi-context protocol for real-world gait simulation

  • Scott, Kirsty
  • Koch, Sarah
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Mobilise-D consortium
Background: Measuring mobility in daily life entails dealing with confounding factors arising from multiple sources, including pathological characteristics, patient specific walking strategies, environment/context, and purpose of the task. The primary aim of this study is to propose and validate a protocol for simulating real-world gait accounting for all these factors within a single set of observations, while ensuring minimisation of participant burden and safety. Methods: The protocol included eight motor tasks at varying speed, incline/steps, surface, path shape, cognitive demand, and included postures that may abruptly alter the participants' strategy of walking. It was deployed in a convenience sample of 108 participants recruited from six cohorts that included older healthy adults (HA) and participants with potentially altered mobility due to Parkinson's disease (PD), multiple sclerosis (MS), proximal femoral fracture (PFF), chronic obstructive pulmonary disease (COPD) or congestive heart failure (CHF). A novelty introduced in the protocol was the tiered approach to increase difficulty both within the same task (e.g., by allowing use of aids or armrests) and across tasks. Results: The protocol proved to be safe and feasible (all participants could complete it and no adverse events were recorded) and the addition of the more complex tasks allowed a much greater spread in walking speeds to be achieved compared to standard straight walking trials. Furthermore, it allowed a representation of a variety of daily life relevant mobility aspects and can therefore be used for the validation of monitoring devices used in real life. Conclusions: The protocol allowed for measuring gait in a variety of pathological conditions suggests that it can also be used to detect changes in gait due to, for example, the onset or progression of a disease, or due to therapy. Trial registration: ISRCTN-12246987., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This study was also supported by the National Institute for Health Research (NIHR) through the Sheffield Biomedical Research Centre (BRC, Grant Number IS-BRC-1215–20017). AY, LA, LR and SDD are also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Center (BRC) based at Newcastle Upon Tyne Hospital NHS Foundation Trust and Newcastle University. AY, LA, LR and SDD are also supported by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust. ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), and from the Generalitat de Catalunya through the CERCA Program. All opinions are those of the authors and not the funders. Neither IMI nor the European Union, EFPIA, NHS, NIHR, DHSC or any Associated Partners are responsible for any use that may be made of the information contained herein.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Real-World gait detection using a wrist-worn inertial sensor: Validation study

  • Kluge, Felix
  • Buekers, Joren
  • Carsin, Anne-Elie
  • García Aymerich, Judith
  • Koch, Sarah
  • Mueller, Arne
Background: Wrist-worn inertial sensors are used in digital health for evaluating mobility in real-world environments. Preceding the estimation of spatiotemporal gait parameters within long-term recordings, gait detection is an important step to identify regions of interest where gait occurs, which requires robust algorithms due to the complexity of arm movements. While algorithms exist for other sensor positions, a comparative validation of algorithms applied to the wrist position on real-world data sets across different disease populations is missing. Furthermore, gait detection performance differences between the wrist and lower back position have not yet been explored but could yield valuable information regarding sensor position choice in clinical studies. Objective: The aim of this study was to validate gait sequence (GS) detection algorithms developed for the wrist position against reference data acquired in a real-world context. In addition, this study aimed to compare the performance of algorithms applied to the wrist position to those applied to lower back-worn inertial sensors. Methods: Participants with Parkinson disease, multiple sclerosis, proximal femoral fracture (hip fracture recovery), chronic obstructive pulmonary disease, and congestive heart failure and healthy older adults (N=83) were monitored for 2.5 hours in the real-world using inertial sensors on the wrist, lower back, and feet including pressure insoles and infrared distance sensors as reference. In total, 10 algorithms for wrist-based gait detection were validated against a multisensor reference system and compared to gait detection performance using lower back-worn inertial sensors. Results: The best-performing GS detection algorithm for the wrist showed a mean (per disease group) sensitivity ranging between 0.55 (SD 0.29) and 0.81 (SD 0.09) and a mean (per disease group) specificity ranging between 0.95 (SD 0.06) and 0.98 (SD 0.02). The mean relative absolute error of estimated walking time ranged between 8.9% (SD 7.1%) and 32.7% (SD 19.2%) per disease group for this algorithm as compared to the reference system. Gait detection performance from the best algorithm applied to the wrist inertial sensors was lower than for the best algorithms applied to the lower back, which yielded mean sensitivity between 0.71 (SD 0.12) and 0.91 (SD 0.04), mean specificity between 0.96 (SD 0.03) and 0.99 (SD 0.01), and a mean relative absolute error of estimated walking time between 6.3% (SD 5.4%) and 23.5% (SD 13%). Performance was lower in disease groups with major gait impairments (eg, patients recovering from hip fracture) and for patients using bilateral walking aids. Conclusions: Algorithms applied to the wrist position can detect GSs with high performance in real-world environments. Those periods of interest in real-world recordings can facilitate gait parameter extraction and allow the quantification of gait duration distribution in everyday life. Our findings allow taking informed decisions on alternative positions for gait recording in clinical studies and public health. Trial registration: ISRCTN Registry 12246987; https://www.isrctn.com/ISRCTN12246987. International registered report identifier (irrid): RR2-10.1136/bmjopen-2021-050785., This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU; grant 820820). The IMI2 JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations. SDD, LR, and AY were also supported by the IMI2 JU project Identifying Digital Endpoints to Assess Fatigue, Sleep and Activities in Daily Living (grant 853981). LA, LR, AY, and SDD were also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear NHS Foundation Trust. JMH and YEB are supported in part by the National Institutes of Health (grant R01AG79133). LA, LR, AY, and SDD were also supported by the NIHR/Wellcome Trust Clinical Research Facility infrastructure at The Newcastle upon Tyne Hospitals NHS Foundation Trust. This study was also supported by the NIHR through the Sheffield BRC (grant IS-BRC-1215-20017). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” program (CEX2018-000806-S) and from the Generalitat de Catalunya through the Centres de Recerca de Catalunya program. All opinions are those of the authors and not the funders. The content in this publication reflects the authors’ view, and neither Innovative Medicines Initiative nor the European Union, European Federation of Pharmaceutical Industries and Associations, National Health Service, NIHR, Department of Health and Social Care, or any associated partners are responsible for any use that may be made of the information contained herein.